At the Bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy
Clinical Review for Basic Researchers: Treating patients with CTLA‐4 and PD‐1 pathway blocking antibodies, plus clinical progress and application of agents in earlier stages of development. It is increasingly appreciated that cancers are recognized by the immune system, and under some circumstances,...
Uloženo v:
| Vydáno v: | Journal of leukocyte biology Ročník 94; číslo 1; s. 41 - 53 |
|---|---|
| Hlavní autoři: | , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
United States
Society for Leukocyte Biology
01.07.2013
|
| Témata: | |
| ISSN: | 0741-5400, 1938-3673, 1938-3673 |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Clinical Review for Basic Researchers: Treating patients with CTLA‐4 and PD‐1 pathway blocking antibodies, plus clinical progress and application of agents in earlier stages of development.
It is increasingly appreciated that cancers are recognized by the immune system, and under some circumstances, the immune system may control or even eliminate tumors. The modulation of signaling via coinhibitory or costimulatory receptors expressed on T cells has proven to be a potent way to amplify antitumor immune responses. This approach has been exploited successfully for the generation of a new class of anticancer therapies, “checkpoint‐blocking” antibodies, exemplified by the recently FDA‐approved agent, ipilimumab, an antibody that blocks the coinhibitory receptor CTLA‐4. Capitalizing on the success of ipilimumab, agents that target a second coinhibitory receptor, PD‐1, or its ligand, PD‐L1, are in clinical development. Lessons learned from treating patients with CTLA‐4 and PD‐1 pathway‐blocking antibodies will be reviewed, with a focus on concepts likely to inform the clinical development and application of agents in earlier stages of development. See related review At the bench: Preclinical rationale for CTLA‐4 and PD‐1 blockade as cancer immunotherapy. |
|---|---|
| AbstractList | Clinical Review for Basic Researchers: Treating patients with CTLA-4 and PD-1 pathway blocking antibodies, plus clinical progress and application of agents in earlier stages of development. It is increasingly appreciated that cancers are recognized by the immune system, and under some circumstances, the immune system may control or even eliminate tumors. The modulation of signaling via coinhibitory or costimulatory receptors expressed on T cells has proven to be a potent way to amplify antitumor immune responses. This approach has been exploited successfully for the generation of a new class of anticancer therapies, “checkpoint-blocking” antibodies, exemplified by the recently FDA-approved agent, ipilimumab, an antibody that blocks the coinhibitory receptor CTLA-4. Capitalizing on the success of ipilimumab, agents that target a second coinhibitory receptor, PD-1, or its ligand, PD-L1, are in clinical development. Lessons learned from treating patients with CTLA-4 and PD-1 pathway-blocking antibodies will be reviewed, with a focus on concepts likely to inform the clinical development and application of agents in earlier stages of development. See related review At the bench: Preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy. Clinical Review for Basic Researchers: Treating patients with CTLA‐4 and PD‐1 pathway blocking antibodies, plus clinical progress and application of agents in earlier stages of development. It is increasingly appreciated that cancers are recognized by the immune system, and under some circumstances, the immune system may control or even eliminate tumors. The modulation of signaling via coinhibitory or costimulatory receptors expressed on T cells has proven to be a potent way to amplify antitumor immune responses. This approach has been exploited successfully for the generation of a new class of anticancer therapies, “checkpoint‐blocking” antibodies, exemplified by the recently FDA‐approved agent, ipilimumab, an antibody that blocks the coinhibitory receptor CTLA‐4. Capitalizing on the success of ipilimumab, agents that target a second coinhibitory receptor, PD‐1, or its ligand, PD‐L1, are in clinical development. Lessons learned from treating patients with CTLA‐4 and PD‐1 pathway‐blocking antibodies will be reviewed, with a focus on concepts likely to inform the clinical development and application of agents in earlier stages of development. See related review At the bench: Preclinical rationale for CTLA‐4 and PD‐1 blockade as cancer immunotherapy. It is increasingly appreciated that cancers are recognized by the immune system, and under some circumstances, the immune system may control or even eliminate tumors. The modulation of signaling via coinhibitory or costimulatory receptors expressed on T cells has proven to be a potent way to amplify antitumor immune responses. This approach has been exploited successfully for the generation of a new class of anticancer therapies, "checkpoint-blocking" antibodies, exemplified by the recently FDA-approved agent, ipilimumab, an antibody that blocks the coinhibitory receptor CTLA-4. Capitalizing on the success of ipilimumab, agents that target a second coinhibitory receptor, PD-1, or its ligand, PD-L1, are in clinical development. Lessons learned from treating patients with CTLA-4 and PD-1 pathway-blocking antibodies will be reviewed, with a focus on concepts likely to inform the clinical development and application of agents in earlier stages of development. See related review At the bench: Preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy. Clinical Review for Basic Researchers: Treating patients with CTLA-4 and PD-1 pathway blocking antibodies, plus clinical progress and application of agents in earlier stages of development. It is increasingly appreciated that cancers are recognized by the immune system, and under some circumstances, the immune system may control or even eliminate tumors. The modulation of signaling via coinhibitory or costimulatory receptors expressed on T cells has proven to be a potent way to amplify antitumor immune responses. This approach has been exploited successfully for the generation of a new class of anticancer therapies, "checkpoint-blocking" antibodies, exemplified by the recently FDA-approved agent, ipilimumab, an antibody that blocks the coinhibitory receptor CTLA-4. Capitalizing on the success of ipilimumab, agents that target a second coinhibitory receptor, PD-1, or its ligand, PD-L1, are in clinical development. Lessons learned from treating patients with CTLA-4 and PD-1 pathway-blocking antibodies will be reviewed, with a focus on concepts likely to inform the clinical development and application of agents in earlier stages of development. See related review At the bench: Preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy.It is increasingly appreciated that cancers are recognized by the immune system, and under some circumstances, the immune system may control or even eliminate tumors. The modulation of signaling via coinhibitory or costimulatory receptors expressed on T cells has proven to be a potent way to amplify antitumor immune responses. This approach has been exploited successfully for the generation of a new class of anticancer therapies, "checkpoint-blocking" antibodies, exemplified by the recently FDA-approved agent, ipilimumab, an antibody that blocks the coinhibitory receptor CTLA-4. Capitalizing on the success of ipilimumab, agents that target a second coinhibitory receptor, PD-1, or its ligand, PD-L1, are in clinical development. Lessons learned from treating patients with CTLA-4 and PD-1 pathway-blocking antibodies will be reviewed, with a focus on concepts likely to inform the clinical development and application of agents in earlier stages of development. See related review At the bench: Preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy. |
| Author | Margaret K. Callahan Jedd D. Wolchok |
| Author_xml | – sequence: 1 givenname: Margaret K. surname: Callahan fullname: Callahan, Margaret K. – sequence: 2 givenname: Jedd D. surname: Wolchok fullname: Wolchok, Jedd D. email: wolchokj@mskcc.org |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/23667165$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkUuLFDEUhYOMOD2jK_dSCxeC1JibRz1cCD3tmwJdjOuQpFLdGVNJm1Rb9L83TfeIimg2geQ7h3PvuUBnPniD0GPAVwBN--LWqSsgQCoK99ACWtqUtKrpGVrgmkHJGcbn6CKlW4wxJRV-gM4JraoaKr5A3XIqpo0prk2fbG9eFqubblmyspC-Lz6_LqFULuiv1q_zy2RV6K1JhfWFll6bWNhx3PmQHaLc7h-i-4N0yTw63Zfoy9s3N6v3Zffp3YfVsis15zg7MjLUwGhLDDOguMRsANJIxnvVK6ZqMIRoDKzVfT6Ea4aHQepWqYzKil6iV0ff7U6NptfGT1E6sY12lHEvgrTi9x9vN2IdvguGeV5ZnQ2enQxi-LYzaRKjTdo4J70JuySAc6gIow35P0obAIzbusnok19j_cxzt-0MwBHQMaQUzSC0neRkwyGldQKwODQqcqPi1GjWPP9Dc2f7dxof6dk6s_8XKj521xizg-TpUbKx681soxFplM7lGYiY57llAkTGfgC_hbvc |
| CitedBy_id | crossref_primary_10_3390_vaccines8040597 crossref_primary_10_1016_j_neo_2016_02_006 crossref_primary_10_1080_08830185_2020_1775827 crossref_primary_10_1159_000509941 crossref_primary_10_1158_0008_5472_CAN_16_2854 crossref_primary_10_3389_fmed_2021_759605 crossref_primary_10_1073_pnas_2200879119 crossref_primary_10_1158_1078_0432_CCR_17_2499 crossref_primary_10_1016_j_trsl_2015_06_019 crossref_primary_10_3389_fphar_2017_00963 crossref_primary_10_1038_s41435_021_00138_4 crossref_primary_10_1039_C9BM00961B crossref_primary_10_3389_fendo_2023_1168245 crossref_primary_10_1200_JCO_2015_60_7879 crossref_primary_10_3389_fonc_2015_00034 crossref_primary_10_1016_j_addr_2017_06_003 crossref_primary_10_1007_s13277_014_2848_2 crossref_primary_10_4049_jimmunol_1402381 crossref_primary_10_1007_s12026_022_09308_6 crossref_primary_10_1016_j_ccell_2014_11_016 crossref_primary_10_1158_0008_5472_CAN_15_0255 crossref_primary_10_1007_s00262_014_1570_7 crossref_primary_10_1053_j_seminoncol_2014_02_007 crossref_primary_10_1038_mtna_2016_102 crossref_primary_10_1371_journal_pone_0206223 crossref_primary_10_1158_2326_6066_CIR_13_0179 crossref_primary_10_1371_journal_pone_0274494 crossref_primary_10_3390_ph16091188 crossref_primary_10_3389_fgene_2022_1061107 crossref_primary_10_1038_mt_2014_47 crossref_primary_10_1007_s00262_016_1846_1 crossref_primary_10_1080_2162402X_2019_1674605 crossref_primary_10_3390_cancers12041025 crossref_primary_10_1177_15330338221150559 crossref_primary_10_1186_s40164_016_0039_0 crossref_primary_10_1517_14728214_2015_1046432 crossref_primary_10_1016_j_intimp_2020_106628 crossref_primary_10_1080_2162402X_2014_1002726 crossref_primary_10_3389_fonc_2019_00530 crossref_primary_10_1007_s12026_017_8931_1 crossref_primary_10_1007_s12017_018_8507_9 crossref_primary_10_1038_mtna_2015_11 crossref_primary_10_3390_toxins6030914 crossref_primary_10_1016_j_biopha_2023_116095 crossref_primary_10_1158_1078_0432_CCR_19_2234 crossref_primary_10_1158_0008_5472_CAN_15_1707 crossref_primary_10_3389_fimmu_2021_689132 crossref_primary_10_1186_s40425_014_0046_9 crossref_primary_10_3390_vaccines7030100 crossref_primary_10_1016_j_addr_2022_114112 crossref_primary_10_3892_etm_2018_7015 crossref_primary_10_4155_fmc_2019_0100 crossref_primary_10_1016_j_febslet_2015_09_022 crossref_primary_10_4161_onci_28582 crossref_primary_10_1016_j_kint_2018_06_025 crossref_primary_10_1007_s12094_021_02659_w crossref_primary_10_4158_EP_2020_0053 crossref_primary_10_3389_fimmu_2019_02453 crossref_primary_10_2147_ITT_S494670 crossref_primary_10_3233_HAB_160307 crossref_primary_10_3390_ijms21155486 crossref_primary_10_1007_s12247_015_9236_3 crossref_primary_10_1172_JCI97642 crossref_primary_10_1007_s10120_024_01514_5 crossref_primary_10_1172_JCI141965 crossref_primary_10_2217_imt_2020_0284 crossref_primary_10_3389_fonc_2019_01073 crossref_primary_10_1080_08820139_2020_1744639 crossref_primary_10_3390_brainsci15080833 crossref_primary_10_1016_j_canlet_2015_05_012 crossref_primary_10_1177_09636897211041587 crossref_primary_10_3390_cancers17050880 crossref_primary_10_1186_s13045_018_0647_8 crossref_primary_10_1007_s10549_021_06384_4 crossref_primary_10_1080_2162402X_2018_1457596 crossref_primary_10_1016_j_clinthera_2014_11_010 crossref_primary_10_1158_2326_6066_CIR_15_0190 crossref_primary_10_1016_j_ctro_2025_101018 crossref_primary_10_1016_j_biomaterials_2016_11_038 crossref_primary_10_1016_j_semcancer_2022_02_016 crossref_primary_10_1200_JCO_2015_61_1509 crossref_primary_10_1245_s10434_014_3794_3 crossref_primary_10_1586_14737140_2016_1121108 crossref_primary_10_1002_pds_5108 crossref_primary_10_1097_PAI_0000000000000903 crossref_primary_10_1007_s43440_020_00152_9 crossref_primary_10_1200_JGO_19_00142 crossref_primary_10_1016_j_omtn_2016_12_002 crossref_primary_10_2217_imt_14_9 crossref_primary_10_1186_s12964_020_00599_6 crossref_primary_10_3389_fonc_2015_00012 crossref_primary_10_3389_fonc_2014_00385 crossref_primary_10_3390_cells13191615 crossref_primary_10_1186_s40425_018_0381_3 crossref_primary_10_1038_nrclinonc_2015_209 crossref_primary_10_3389_fonc_2022_879391 crossref_primary_10_1016_j_jconrel_2021_02_002 crossref_primary_10_1158_2326_6066_CIR_21_0594 crossref_primary_10_3389_fonc_2019_00682 crossref_primary_10_1038_s41598_018_27994_x crossref_primary_10_1186_s12885_022_10011_w crossref_primary_10_1186_s40425_016_0114_4 crossref_primary_10_1016_j_it_2015_02_008 crossref_primary_10_3390_immuno1040029 crossref_primary_10_1007_s10238_023_01031_2 crossref_primary_10_1007_s12026_014_8524_1 crossref_primary_10_2217_imt_2016_0002 crossref_primary_10_1080_14712598_2016_1177018 crossref_primary_10_7774_cevr_2015_4_2_145 crossref_primary_10_1177_27325016211013880 crossref_primary_10_1172_JCI80566 crossref_primary_10_1097_PPO_0000000000000107 crossref_primary_10_1016_j_immuni_2019_11_002 crossref_primary_10_1155_2023_5867047 crossref_primary_10_12688_f1000research_8109_1 crossref_primary_10_1634_theoncologist_2015_0421 crossref_primary_10_2217_imt_15_49 crossref_primary_10_3390_cancers14102545 crossref_primary_10_3390_ph16071042 crossref_primary_10_2217_imt_2016_0009 crossref_primary_10_1038_s41570_018_0023_9 crossref_primary_10_2217_imt_2016_0014 crossref_primary_10_1038_srep30923 crossref_primary_10_1155_2015_191832 crossref_primary_10_3389_fimmu_2017_00619 crossref_primary_10_3389_fimmu_2021_806043 crossref_primary_10_1111_jgh_12708 crossref_primary_10_3389_fimmu_2023_1139595 crossref_primary_10_1002_jcph_2150 crossref_primary_10_3389_fimmu_2014_00206 crossref_primary_10_3390_v7112923 crossref_primary_10_1073_pnas_2419888122 crossref_primary_10_1007_s12032_025_02605_8 crossref_primary_10_1158_0008_5472_CAN_13_1504 crossref_primary_10_3390_ijms222111318 crossref_primary_10_1016_j_jaad_2020_04_105 crossref_primary_10_3390_ijms22062954 crossref_primary_10_3390_ijms222111694 crossref_primary_10_1089_thy_2013_0680 crossref_primary_10_1016_j_bbrc_2022_06_059 crossref_primary_10_1016_j_it_2013_10_001 crossref_primary_10_1158_2326_6066_CIR_13_0219 crossref_primary_10_1080_2162402X_2018_1554969 crossref_primary_10_1016_j_critrevonc_2023_104135 crossref_primary_10_1021_acs_chemrestox_6b00357 crossref_primary_10_1016_j_bbcan_2015_06_007 crossref_primary_10_1016_j_coi_2015_01_006 crossref_primary_10_1038_cti_2014_18 crossref_primary_10_1016_j_omto_2016_11_005 crossref_primary_10_1155_2015_820813 crossref_primary_10_1186_s12935_024_03293_6 crossref_primary_10_3389_fimmu_2017_01804 crossref_primary_10_3390_biomedicines9101479 crossref_primary_10_1016_j_jcyt_2014_02_017 crossref_primary_10_1111_dth_15747 crossref_primary_10_1016_j_ejca_2016_02_010 crossref_primary_10_1038_s41388_018_0288_y crossref_primary_10_1016_j_biopha_2017_11_126 crossref_primary_10_1371_journal_pone_0150030 crossref_primary_10_1016_j_ccr_2022_214788 crossref_primary_10_1016_j_critrevonc_2019_07_006 crossref_primary_10_1016_j_canlet_2014_11_001 crossref_primary_10_1093_toxsci_kfae058 crossref_primary_10_1016_j_cps_2021_05_007 crossref_primary_10_1016_j_pharmthera_2014_01_001 crossref_primary_10_1080_08923973_2018_1437625 crossref_primary_10_1002_cncr_30449 crossref_primary_10_1073_pnas_1706559114 crossref_primary_10_1158_2326_6066_CIR_14_0161 crossref_primary_10_2217_imt_14_46 crossref_primary_10_1158_0008_5472_CAN_16_0194 crossref_primary_10_1586_14760584_2014_852961 crossref_primary_10_1038_s41401_022_00910_w crossref_primary_10_1111_cts_12391 crossref_primary_10_1002_ijc_28973 crossref_primary_10_3390_jcm10204767 crossref_primary_10_1177_15330338251319394 crossref_primary_10_3390_cells13040337 crossref_primary_10_3390_ijms21238993 crossref_primary_10_1186_s12645_023_00209_3 crossref_primary_10_1038_nri3789 crossref_primary_10_3389_fimmu_2022_914890 crossref_primary_10_1111_cas_16063 crossref_primary_10_1007_s11912_021_01052_8 crossref_primary_10_1016_j_intimp_2023_110312 crossref_primary_10_1038_s41423_018_0168_y crossref_primary_10_1055_s_0043_1769092 crossref_primary_10_3390_vaccines2020422 crossref_primary_10_1016_j_addr_2015_10_021 crossref_primary_10_1097_CMR_0000000000000672 crossref_primary_10_1016_j_intimp_2024_113365 crossref_primary_10_1016_j_ctrv_2017_06_002 crossref_primary_10_1007_s12272_015_0566_y crossref_primary_10_1111_exd_13069 crossref_primary_10_3389_fimmu_2018_02861 crossref_primary_10_1080_2162402X_2018_1445457 crossref_primary_10_1016_j_cvsm_2017_10_004 crossref_primary_10_1038_nri3799 crossref_primary_10_1111_imr_12136 crossref_primary_10_3389_fimmu_2018_00442 crossref_primary_10_1016_j_febslet_2013_10_015 crossref_primary_10_4049_jimmunol_1500300 crossref_primary_10_1002_cnr2_1947 crossref_primary_10_1016_j_neo_2015_08_004 crossref_primary_10_1007_s12328_024_02044_4 crossref_primary_10_1038_srep44320 crossref_primary_10_3390_molecules27051482 crossref_primary_10_1016_j_ebiom_2023_104834 crossref_primary_10_1016_j_anndiagpath_2016_09_012 crossref_primary_10_1128_JVI_01263_17 crossref_primary_10_1186_s40425_019_0754_2 crossref_primary_10_1007_s40618_025_02608_2 crossref_primary_10_1093_nop_npu029 crossref_primary_10_1186_s13148_017_0314_x crossref_primary_10_1007_s11523_016_0437_6 crossref_primary_10_1097_IGC_0000000000000979 crossref_primary_10_1189_jlb_3MA0717_283 crossref_primary_10_3390_jcm8101667 crossref_primary_10_3389_fimmu_2024_1385781 crossref_primary_10_1016_j_bbcan_2014_01_004 crossref_primary_10_3389_fimmu_2018_00341 crossref_primary_10_1007_s12032_017_0972_8 crossref_primary_10_1146_annurev_cancerbio_042716_094839 crossref_primary_10_3389_fphar_2020_595498 crossref_primary_10_3233_CBM_181368 |
| Cites_doi | 10.1016/j.febslet.2005.12.093 10.1111/j.1365-2249.2009.03912.x 10.1158/0008-5472.1089.65.3 10.1189/jlb.1212621 10.1158/1078-0432.CCR-04-0428 10.1200/JCO.2011.38.7886 10.1007/s00262-011-1172-6 10.1007/s10555-011-9283-2 10.1016/j.coi.2010.11.013 10.4049/jimmunol.180.2.774 10.1016/j.urology.2005.06.010 10.1002/j.1460-2075.1992.tb05481.x 10.1200/JCO.2005.04.5716 10.1093/annonc/mds258 10.1038/nri823 10.1073/pnas.1110814108 10.1097/CMR.0b013e32832e0bff 10.1073/pnas.1003345107 10.1002/cncr.21470 10.1073/pnas.0813175106 10.1016/0952-7915(95)80077-8 10.1056/NEJMoa1003466 10.1038/icb.1975.3 10.1158/1078-0432.CCR-12-0409 10.1080/713774061 10.1056/NEJMoa1112824 10.1002/cncr.24951 10.1200/JCO.2005.04.5252 10.1186/1479-5876-9-204 10.1073/pnas.192461099 10.4049/jimmunol.170.3.1257 10.1016/j.acthis.2006.01.003 10.1200/jco.2012.30.15_suppl.2512 10.1073/pnas.0406351101 10.1016/j.jneuroim.2004.06.013 10.1158/1078-0432.CCR-09-1624 10.1002/cncr.22588 10.4049/jimmunol.0803245 10.1172/JCI31184 10.1084/jem.190.3.355 10.1073/pnas.0806075105 10.1007/s00262-008-0653-8 10.1158/1078-0432.CCR-09-2033 10.1182/blood-2008-12-195792 10.1056/NEJMoa1200694 10.1530/EJE-12-0167 10.1056/NEJMoa1001294 10.1158/1078-0432.CCR-07-4079 10.1073/pnas.0915174107 10.1038/nm863 10.1097/01.pas.0000209855.28282.ce 10.1073/pnas.96.20.11476 10.4161/onci.20074 10.1158/1078-0432.CCR-10-0569 10.1016/j.humpath.2007.11.012 10.1146/annurev-immunol-032712-100008 10.1158/1078-0432.CCR-12-1362 10.1158/1078-0432.CCR-06-2318 10.1158/1078-0432.CCR-09-0265 10.1007/s00262-006-0266-z 10.1158/1078-0432.CCR-11-1823 10.1093/intimm/dxm091 10.1158/0008-5472.CAN-08-3529 10.2147/CMAR.S31873 10.1073/pnas.94.15.8099 10.1200/JCO.2009.25.0597 10.1073/pnas.0611533104 10.1200/jco.2009.27.15_suppl.5138 10.1200/jco.2010.28.15_suppl.7531 10.1200/jco.2010.28.15_suppl.2555 10.1016/S1074-7613(00)80123-5 10.1158/1078-0432.CCR-06-2746 10.1111/j.1600-065X.2008.00649.x 10.1158/1078-0432.728.11.2 10.1200/jco.2008.26.15_suppl.lba9011 10.1016/S0165-5728(96)00168-3 10.1016/j.smim.2010.03.001 10.1097/CJI.0b013e318156e47e 10.1093/annonc/mds404 10.1038/70932 10.1146/annurev.immunol.22.012703.104803 10.1084/jem.192.7.1027 10.1073/pnas.0810114105 10.1038/nm730 10.1097/CJI.0b013e3181c01fcb 10.1200/jco.2009.27.15_suppl.3020 10.1200/jco.2009.27.15_suppl.5144 10.1158/0008-5472.CAN-03-3025 10.1182/blood-2006-10-051482 10.1126/science.271.5256.1734 10.1016/S1470-2045(09)70334-1 10.1158/1078-0432.CCR-10-0505 10.1126/scitranslmed.3003689 10.1084/jem.20031074 10.1158/1078-0432.CCR-04-2672 10.1056/NEJMoa1200690 10.1097/CJI.0b013e3181affbf0 10.1093/intimm/dxh194 10.1084/jem.165.2.302 10.1053/j.seminoncol.2010.09.007 10.1200/jco.2010.28.15_suppl.2609 10.1097/CJI.0b013e3181eec14c 10.1056/NEJMoa1104621 10.1158/0008-5472.CAN-05-4303 10.4049/jimmunol.169.10.5538 10.1056/NEJMc1203984 10.1126/science.169.3950.1042 10.1007/s11102-009-0193-z |
| ContentType | Journal Article |
| Copyright | 2013 Society for Leukocyte Biology 2013 Society for Leukocyte Biology 2013 |
| Copyright_xml | – notice: 2013 Society for Leukocyte Biology – notice: 2013 Society for Leukocyte Biology 2013 |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 7T5 H94 5PM |
| DOI | 10.1189/jlb.1212631 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic Immunology Abstracts AIDS and Cancer Research Abstracts PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic AIDS and Cancer Research Abstracts Immunology Abstracts |
| DatabaseTitleList | MEDLINE CrossRef AIDS and Cancer Research Abstracts MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Anatomy & Physiology Biology |
| EISSN | 1938-3673 |
| EndPage | 53 |
| ExternalDocumentID | PMC4051187 23667165 10_1189_jlb_1212631 JLB0041 www94_1_41 |
| Genre | reviewArticle Journal Article Review Research Support, N.I.H., Extramural |
| GrantInformation_xml | – fundername: NCI NIH HHS grantid: P30 CA008748 |
| GroupedDBID | - 0VX 1OC 29K 2WC 4.4 53G 5GY 5RE AAZKR ABCUV ABFLS ACGFS ACPOU ACPRK ACXQS ADACO ADBBV ADDAD ADXAS ADZMN AENEX AEUQT AFRAH ALMA_UNASSIGNED_HOLDINGS ALUQN BFHJK BQCPF C45 CS3 D-I DCZOG DRFUL DRSTM DU5 E3Z EBS EJD F5P GX1 H13 HZ K-O L7B LATKE LEEKS LUTES LYRES MEWTI MSJOP MXJOP OK1 OVD P2P P2W RHF RHI ROL SJN SUPJJ TSL WOHZO WOQ ZA5 ZZTAW --- .GJ 0R~ 18M 33P 5WD AABZA AACZT AAMMB AAPGJ AAPXW AARHZ AASGY AAUAY AAVAP AAWDT AAXRX ABDFA ABEFU ABEJV ABGNP ABIME ABJNI ABLJU ABMNT ABNHQ ABPIB ABPQP ABPTD ABVGC ABWST ABXVV ABXZS ABZEO ACAHQ ACCZN ACFRR ACGFO ACUTJ ACVCV ACXBN ACZBC ADGKP ADIPN ADKYN ADMTO ADNBA ADOZA ADQBN ADVEK ADVOB AEFGJ AFFNX AFFQV AFGWE AFYAG AGMDO AGORE AGQXC AGXDD AHGBF AHMMS AI. AIDQK AIDYY AIURR AJAOE AJBYB AJDVS AJEEA AJNCP ALXQX AMYDB ANFBD APJGH ATGXG AVNTJ BCRHZ EMOBN F9R HZ~ KOP NU- O9- OBFPC OBOKY OCZFY OJZSN OPAEJ OWPYF RJQFR ROX TCN TEORI TMA TR2 VH1 W8F YHG ZGI ZXP AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 7T5 H94 5PM |
| ID | FETCH-LOGICAL-c5501-b42f714392e4e1b5a04f128a45dbdb4b71e22c0149cdddd25c40ffac9bba04a63 |
| IEDL.DBID | DRFUL |
| ISICitedReferencesCount | 279 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000328840800006&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0741-5400 1938-3673 |
| IngestDate | Tue Sep 30 16:53:40 EDT 2025 Sun Sep 28 12:20:03 EDT 2025 Thu Oct 02 09:53:18 EDT 2025 Mon Jul 21 05:45:40 EDT 2025 Sat Nov 29 02:55:32 EST 2025 Tue Nov 18 22:24:49 EST 2025 Wed Aug 20 07:25:59 EDT 2025 Tue Jan 05 20:17:10 EST 2021 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | overall survival endpoints tumor |
| Language | English |
| License | https://academic.oup.com/pages/standard-publication-reuse-rights |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c5501-b42f714392e4e1b5a04f128a45dbdb4b71e22c0149cdddd25c40ffac9bba04a63 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 ObjectType-Article-2 ObjectType-Feature-1 |
| OpenAccessLink | http://doi.org/10.1189/jlb.1212631 |
| PMID | 23667165 |
| PQID | 1381100978 |
| PQPubID | 23479 |
| PageCount | 13 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_4051187 proquest_miscellaneous_1551624382 proquest_miscellaneous_1381100978 pubmed_primary_23667165 crossref_citationtrail_10_1189_jlb_1212631 crossref_primary_10_1189_jlb_1212631 wiley_primary_10_1189_jlb_1212631_JLB0041 highwire_smallpub2_www94_1_41 |
| ProviderPackageCode | RHF RHI |
| PublicationCentury | 2000 |
| PublicationDate | July 2013 |
| PublicationDateYYYYMMDD | 2013-07-01 |
| PublicationDate_xml | – month: 07 year: 2013 text: July 2013 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: Bethesda, MD, USA |
| PublicationTitle | Journal of leukocyte biology |
| PublicationTitleAlternate | J Leukoc Biol |
| PublicationYear | 2013 |
| Publisher | Society for Leukocyte Biology |
| Publisher_xml | – name: Society for Leukocyte Biology |
| References | 2012; 61 2004; 22 2010; 11 2007; 104 2004; 64 1970; 169 2010; 16 2006; 30 2012; 167 2012; 366 2010; 13 2010; 107 2002; 99 2008; 39 2009; 157 2005; 65 1975; 53 2012; 18 2008; 105 2008; 224 2007; 30 1992; 11 2007; 109 94 2005; 66 2009; 114 2003; 198 2010; 22 2009; 58 1997; 94 2006; 24 2010; 116 2013; 13 2010; 28 2006; 66 2005; 104 1997; 57 1999; 59 2003; 9 2008; 26 1999; 11 1999; 96 2011; 23 2009; 19 2012; 23 2011; 364 2009; 15 2004; 101 2010; 33 2007; 19 2009; 69 2010; 37 1987; 165 2002; 9 2012 1999; 190 2009; 182 2002; 8 2010; 363 2008; 14 2002; 2 2011; 30 2003; 170 2007; 56 1999; 5 2012; 32 2007; 13 2009; 27 2012; 30 1995; 7 2000; 192 2011; 9 2004; 10 2004; 155 2008; 180 1997; 73 2006; 108 2011; 108 2009; 32 2007; 117 2012; 1 2007; 110 2002; 169 2002; 21 2013; 31 1996; 271 2006; 580 2005; 17 2012; 4 2003; 63 2005; 11 2009; 106 Yamazaki (2023013012333151700_B50) 2002; 169 Patnaik (2023013012333151700_B80) 2012; 30 Demaria (2023013012333151700_B113) 2005; 11 Small (2023013012333151700_B46) 2006; 24 Ku (2023013012333151700_B84) 2010; 116 Sotomayor (2023013012333151700_B11) 1999; 96 Slovin (2023013012333151700_B100) 2009; 27 Lafferty (2023013012333151700_B3) 1975; 53 Chen (2023013012333151700_B91) 2009; 106 Dunn (2023013012333151700_B5) 2004; 22 Tchekmedyian (2023013012333151700_B22) 2002; 21 Ji (2023013012333151700_B96) 2012; 61 Brown (2023013012333151700_B64) 2003; 170 Hurwitz (2023013012333151700_B44) 1997; 73 Dong (2023013012333151700_B76) 1999; 5 Grosso (2023013012333151700_B98) 2013; 13 Thompson (2023013012333151700_B55) 2005; 104 Wintterle (2023013012333151700_B63) 2003; 63 Postow (2023013012333151700_B49) 2012; 18 Forde (2023013012333151700_B34) 2012; 32 Liu (2023013012333151700_B54) 2007; 110 Postow (2023013012333151700_B115) 2012; 366 Burmeister (2023013012333151700_B89) 2008; 180 Hiniker (2023013012333151700_B116) 2012; 366 Hamid (2023013012333151700_B81) 2012 Taube (2023013012333151700_B97) 2012; 4 Yang (2023013012333151700_B104) 2007; 30 Shrikant (2023013012333151700_B10) 1999; 11 Sosman (2023013012333151700_B79) 2012 Strome (2023013012333151700_B16) 2003; 63 Berger (2023013012333151700_B78) 2008; 14 Jenkins (2023013012333151700_B2) 1987; 165 Bretscher (2023013012333151700_B4) 1970; 169 Wong (2023013012333151700_B72) 2007; 19 Carthon (2023013012333151700_B93) 2010; 16 Dillard (2023013012333151700_B40) 2010; 13 Konishi (2023013012333151700_B66) 2004; 10 Nakanishi (2023013012333151700_B58) 2007; 56 Kantoff (2023013012333151700_B47) 2010; 28 Kirkwood (2023013012333151700_B26) 2010; 16 Baxter (2023013012333151700_B1) 2002; 2 Wolchok (2023013012333151700_B38) 2012; 23 Berman (2023013012333151700_B83) 2009; 27 Dewan (2023013012333151700_B112) 2009; 15 Mangsbo (2023013012333151700_B107) 2010; 33 Kantoff (2023013012333151700_B45) 2010; 363 Peggs (2023013012333151700_B6) 2009; 157 Grosso (2023013012333151700_B13) 2007; 117 Matsuzaki (2023013012333151700_B74) 2010; 107 Chen (2023013012333151700_B82) 2012; 18 Chakravarty (2023013012333151700_B114) 1999; 59 Thompson (2023013012333151700_B65) 2006; 66 Radhakrishnan (2023013012333151700_B19) 2004; 64 Eppihimer (2023013012333151700_B51) 2002; 9 Di Giacomo (2023013012333151700_B33) 2010; 37 Inman (2023013012333151700_B57) 2007; 109 Ishida (2023013012333151700_B21) 1992; 11 Hamid (2023013012333151700_B95) 2011; 9 Intlekofer (2023013012333151700_B20); 94 Hamanishi (2023013012333151700_B59) 2007; 104 Ma (2023013012333151700_B110) 2010; 22 Freeman (2023013012333151700_B77) 2000; 192 Kroemer (2023013012333151700_B111) 2012; 1 Lee (2023013012333151700_B53) 2006; 580 Fourcade (2023013012333151700_B73) 2009; 182 Maur (2023013012333151700_B35) 2012; 30 Kaehler (2023013012333151700_B41) 2009; 19 Hodi (2023013012333151700_B24) 2010; 363 van Elsas (2023013012333151700_B43) 1999; 190 Curran (2023013012333151700_B106) 2010; 107 Topalian (2023013012333151700_B30) 2012; 366 Ribas (2023013012333151700_B27) 2008; 26 Yang (2023013012333151700_B9) 1997; 57 Wolchok (2023013012333151700_B29) 2009; 15 Gajewski (2023013012333151700_B94) 2011; 23 Dong (2023013012333151700_B62) 2002; 8 Yang (2023013012333151700_B85) 2010; 28 Mohebtash (2023013012333151700_B101) 2009; 27 Andrews (2023013012333151700_B36) 2012; 4 Hirano (2023013012333151700_B14) 2005; 65 Kroemer (2023013012333151700_B108) 2013; 31 Thompson (2023013012333151700_B71) 2005; 66 Vonderheide (2023013012333151700_B92) 2010; 16 Small (2023013012333151700_B102) 2007; 13 Wu (2023013012333151700_B61) 2006; 108 Tamura (2023013012333151700_B70) 2005; 11 Iwai (2023013012333151700_B18) 2005; 17 Leach (2023013012333151700_B7) 1996; 271 Ahmadzadeh (2023013012333151700_B75) 2009; 114 Weber (2023013012333151700_B32) 2009; 58 Liakou (2023013012333151700_B90) 2008; 105 Fong (2023013012333151700_B99) 2009; 69 Thompson (2023013012333151700_B56) 2004; 101 Prieto (2023013012333151700_B48) 2012; 18 Yuan (2023013012333151700_B86) 2008; 105 Royal (2023013012333151700_B105) 2010; 33 Beck (2023013012333151700_B37) 2006; 24 Nomi (2023013012333151700_B60) 2007; 13 Peggs (2023013012333151700_B42) 2008; 224 Iwai (2023013012333151700_B17) 2002; 99 Brahmer (2023013012333151700_B31) 2012; 366 Schreiner (2023013012333151700_B52) 2004; 155 Juszczak (2023013012333151700_B39) 2012; 167 Rosenwald (2023013012333151700_B69) 2003; 198 Wolchok (2023013012333151700_B23) 2010; 11 Allison (2023013012333151700_B12) 1995; 7 Dorfman (2023013012333151700_B68) 2006; 30 Ma (2023013012333151700_B109) 2011; 30 Robert (2023013012333151700_B25) 2011; 364 Yuan (2023013012333151700_B87) 2011; 108 Xerri (2023013012333151700_B67) 2008; 39 Lynch (2023013012333151700_B103) 2010; 28 Curiel (2023013012333151700_B15) 2003; 9 Goff (2023013012333151700_B88) 2009; 32 Marshall (2023013012333151700_B28) 2010; 28 Kwon (2023013012333151700_B8) 1997; 94 16530813 - Acta Histochem. 2006;108(1):19-24 12093010 - Nat Rev Immunol. 2002 Jun;2(6):439-46 22754758 - Oncoimmunology. 2012 Jul 1;1(4):407-408 22658127 - N Engl J Med. 2012 Jun 28;366(26):2443-54 16413538 - FEBS Lett. 2006 Feb 6;580(3):755-62 1396582 - EMBO J. 1992 Nov;11(11):3887-95 20385810 - Proc Natl Acad Sci U S A. 2010 Apr 27;107(17):7875-80 20143434 - Cancer. 2010 Apr 1;116(7):1767-75 18483370 - Clin Cancer Res. 2008 May 15;14(10):3044-51 23157435 - Annu Rev Immunol. 2013;31:51-72 17363736 - Blood. 2007 Jul 1;110(1):296-304 21298323 - Cancer Metastasis Rev. 2011 Mar;30(1):71-82 20403709 - Semin Immunol. 2010 Jun;22(3):113-24 19706802 - Clin Cancer Res. 2009 Sep 1;15(17):5379-88 12975453 - J Exp Med. 2003 Sep 15;198(6):851-62 20004617 - Lancet Oncol. 2010 Feb;11(2):155-64 23390376 - Cancer Immun. 2013;13:5 23060594 - Anticancer Res. 2012 Oct;32(10):4607-8 20100959 - J Clin Oncol. 2010 Mar 1;28(7):1099-105 22918923 - Ann Oncol. 2012 Sep;23 Suppl 8:viii15-21 15297412 - Clin Cancer Res. 2004 Aug 1;10(15):5094-100 9058759 - J Neuroimmunol. 1997 Mar;73(1-2):57-62 15342209 - J Neuroimmunol. 2004 Oct;155(1-2):172-82 18049334 - J Immunother. 2007 Nov-Dec;30(8):825-30 18759925 - Immunol Rev. 2008 Aug;224:141-65 16710025 - J Clin Oncol. 2006 May 20;24(15):2283-9 15611321 - Int Immunol. 2005 Feb;17(2):133-44 12704383 - Nat Med. 2003 May;9(5):562-7 17186290 - Cancer Immunol Immunother. 2007 Aug;56(8):1173-82 18479731 - Hum Pathol. 2008 Jul;39(7):1050-8 15705911 - Cancer Res. 2005 Feb 1;65(3):1089-96 20086001 - Clin Cancer Res. 2010 Feb 1;16(3):1042-8 19147575 - Cancer Res. 2009 Jan 15;69(2):609-15 17340590 - Cancer. 2007 Apr 15;109(8):1499-505 22338019 - Clin Cancer Res. 2012 Apr 1;18(7):1821-3 23625198 - J Leukoc Biol. 2013 Jul;94(1):25-39 10549630 - Immunity. 1999 Oct;11(4):483-93 16819321 - Am J Surg Pathol. 2006 Jul;30(7):802-10 22495490 - Eur J Endocrinol. 2012 Jul;167(1):1-5 20818862 - N Engl J Med. 2010 Jul 29;363(5):411-22 19198837 - Cancer Immunol Immunother. 2009 May;58(5):823-30 20445343 - J Immunother. 2010 Apr;33(3):225-35 3029267 - J Exp Med. 1987 Feb 1;165(2):302-19 22271879 - Clin Cancer Res. 2012 Apr 1;18(7):2039-47 21933959 - Proc Natl Acad Sci U S A. 2011 Oct 4;108(40):16723-8 17932562 - J Clin Invest. 2007 Nov;117(11):3383-92 12421930 - J Immunol. 2002 Nov 15;169(10):5538-45 19423728 - Blood. 2009 Aug 20;114(8):1537-44 14559843 - Cancer Res. 2003 Oct 1;63(19):6501-5 9223321 - Proc Natl Acad Sci U S A. 1997 Jul 22;94(15):8099-103 22461641 - Sci Transl Med. 2012 Mar 28;4(127):127ra37 19934295 - Clin Cancer Res. 2009 Dec 1;15(23):7412-20 20842054 - J Immunother. 2010 Oct;33(8):828-33 16115907 - Clin Cancer Res. 2005 Aug 15;11(16):5708-17 15032581 - Annu Rev Immunol. 2004;22:329-60 19659765 - Clin Exp Immunol. 2009 Jul;157(1):9-19 22123319 - J Transl Med. 2011;9:204 18178815 - J Immunol. 2008 Jan 15;180(2):774-82 10581077 - Nat Med. 1999 Dec;5(12):1365-9 19380770 - J Immunol. 2009 May 1;182(9):5240-9 17898045 - Int Immunol. 2007 Oct;19(10):1223-34 19202079 - Proc Natl Acad Sci U S A. 2009 Feb 24;106(8):2729-34 8573312 - Curr Opin Immunol. 1995 Oct;7(5):682-6 4194660 - Science. 1970 Sep 11;169(3950):1042-9 10430624 - J Exp Med. 1999 Aug 2;190(3):355-66 20460488 - Clin Cancer Res. 2010 May 15;16(10):2861-71 9307290 - Cancer Res. 1997 Sep 15;57(18):4036-41 22397654 - N Engl J Med. 2012 Mar 8;366(10):925-31 16809734 - J Clin Oncol. 2006 Jul 1;24(19):3089-94 20479064 - Clin Cancer Res. 2010 Jul 1;16(13):3485-94 8596936 - Science. 1996 Mar 22;271(5256):1734-6 25977344 - Clin Cancer Res. 2015 Oct 1;21(19):4286-93 238498 - Aust J Exp Biol Med Sci. 1975 Feb;53(1):27-42 22203769 - J Clin Oncol. 2012 Feb 20;30(6):e76-8 23049279 - Cancer Manag Res. 2012;4:299-307 20525992 - N Engl J Med. 2010 Aug 19;363(8):711-23 16194701 - Urology. 2005 Nov;66(5 Suppl):10-4 19074257 - Proc Natl Acad Sci U S A. 2008 Dec 23;105(51):20410-5 17404099 - Clin Cancer Res. 2007 Apr 1;13(7):2151-7 19639414 - Pituitary. 2010;13(1):29-38 12091876 - Nat Med. 2002 Aug;8(8):793-800 21185705 - Curr Opin Immunol. 2011 Apr;23(2):286-92 21639810 - N Engl J Med. 2011 Jun 30;364(26):2517-26 15256470 - Cancer Res. 2004 Jul 15;64(14):4965-72 16208700 - Cancer. 2005 Nov 15;104(10):2084-91 21074065 - Semin Oncol. 2010 Oct;37(5):499-507 20160101 - Proc Natl Acad Sci U S A. 2010 Mar 2;107(9):4275-80 19512947 - Melanoma Res. 2009 Oct;19(5):333-4 10626784 - Cancer Res. 1999 Dec 15;59(24):6028-32 12218188 - Proc Natl Acad Sci U S A. 2002 Sep 17;99(19):12293-7 22146893 - Cancer Immunol Immunother. 2012 Jul;61(7):1019-31 22658128 - N Engl J Med. 2012 Jun 28;366(26):2455-65 15701862 - Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):728-34 16585157 - Cancer Res. 2006 Apr 1;66(7):3381-5 11932780 - Microcirculation. 2002 Apr;9(2):133-45 14612546 - Cancer Res. 2003 Nov 1;63(21):7462-7 17363537 - Clin Cancer Res. 2007 Mar 15;13(6):1810-5 11015443 - J Exp Med. 2000 Oct 2;192(7):1027-34 10500201 - Proc Natl Acad Sci U S A. 1999 Sep 28;96(20):11476-81 15569934 - Proc Natl Acad Sci U S A. 2004 Dec 7;101(49):17174-9 18818309 - Proc Natl Acad Sci U S A. 2008 Sep 30;105(39):14987-92 23087408 - Clin Cancer Res. 2012 Dec 15;18(24):6580-7 17360651 - Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3360-5 22621637 - N Engl J Med. 2012 May 24;366(21):2035; author reply 2035-6 19752745 - J Immunother. 2009 Oct;32(8):884-5 12538684 - J Immunol. 2003 Feb 1;170(3):1257-66 |
| References_xml | – volume: 30 start-page: 825 year: 2007 end-page: 830 article-title: Ipilimumab (anti‐CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis publication-title: J. Immunother. – volume: 169 start-page: 1042 year: 1970 end-page: 1049 article-title: A theory of self‐nonself discrimination publication-title: Science – volume: 31 start-page: 51 year: 2013 end-page: 72 article-title: Immunogenic cell death in cancer therapy publication-title: Annu. Rev. Immunol. – volume: 109 start-page: 1499 year: 2007 end-page: 1505 article-title: PD‐L1 (B7‐H1) expression by urothelial carcinoma of the bladder and BCG‐induced granulomata: associations with localized stage progression publication-title: Cancer – volume: 7 start-page: 682 year: 1995 end-page: 686 article-title: Manipulation of costimulatory signals to enhance antitumor T‐cell responses publication-title: Curr. Opin. Immunol. – volume: 11 start-page: 483 year: 1999 end-page: 493 article-title: CTLA‐4 blockade reverses CD8+ T cell tolerance to tumor by a CD4+ T cell‐ and IL‐2‐dependent mechanism publication-title: Immunity – volume: 13 start-page: 5 year: 2013 article-title: CTLA‐4 blockade in tumor models: an overview of preclinical and translational research publication-title: Cancer Immun. – volume: 73 start-page: 57 year: 1997 end-page: 62 article-title: Specific blockade of CTLA‐4/B7 interactions results in exacerbated clinical and histologic disease in an actively‐induced model of experimental allergic encephalomyelitis publication-title: J. Neuroimmunol. – volume: 9 start-page: 133 year: 2002 end-page: 145 article-title: Expression and regulation of the PD‐L1 immunoinhibitory molecule on microvascular endothelial cells publication-title: Microcirculation – volume: 30 start-page: e76 year: 2012 end-page: e78 article-title: Posterior reversible encephalopathy syndrome during ipilimumab therapy for malignant melanoma publication-title: J. Clin. Oncol. – volume: 192 start-page: 1027 year: 2000 end-page: 1034 article-title: Engagement of the PD‐1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation publication-title: J. Exp. Med. – volume: 13 start-page: 2151 year: 2007 end-page: 2157 article-title: Clinical significance and therapeutic potential of the programmed death‐1 ligand/programmed death‐1 pathway in human pancreatic cancer publication-title: Clin. Cancer Res. – volume: 30 start-page: 802 year: 2006 end-page: 810 article-title: Programmed death‐1 (PD‐1) is a marker of germinal center‐associated T cells and angioimmunoblastic T‐cell lymphoma publication-title: Am. J. Surg. Pathol. – volume: 27 year: 2009 article-title: Association of peripheral blood absolute lymphocyte count (ALC) and clinical activity in patients (pts) with advanced melanoma treated with ipilimumab publication-title: J. Clin. Oncol. – volume: 14 start-page: 3044 year: 2008 end-page: 3051 article-title: Phase I safety and pharmacokinetic study of CT‐011, a humanized antibody interacting with PD‐1, in patients with advanced hematologic malignancies publication-title: Clin. Cancer Res. – volume: 114 start-page: 1537 year: 2009 end-page: 1544 article-title: Tumor antigen‐specific CD8 T cells infiltrating the tumor express high levels of PD‐1 and are functionally impaired publication-title: Blood – volume: 94 start-page: 25 end-page: 39 article-title: At the bench: Preclinical rationale for CTLA‐4 and PD‐1 blockade as cancer immunotherapy publication-title: J. Leukoc. Biol. – volume: 105 start-page: 14987 year: 2008 end-page: 14992 article-title: CTLA‐4 blockade increases IFN ‐producing CD4 + ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients publication-title: Proc. Natl. Acad. Sci. USA – volume: 4 start-page: 299 year: 2012 end-page: 307 article-title: Characteristics and management of immunerelated adverse effects associated with ipilimumab, a new immunotherapy for metastatic melanoma publication-title: Cancer Manag. Res. – volume: 28 issue: Suppl; abs. 2609 year: 2010 article-title: Evaluation of baseline serum C‐reactive protein (CRP) and benefit from tremelimumab compared to chemotherapy in first‐line melanoma publication-title: J. Clin. Oncol. – volume: 2 start-page: 439 year: 2002 end-page: 446 article-title: Activation rules: the two‐signal theories of immune activation publication-title: Nat. Rev. Immunol. – volume: 61 start-page: 1019 year: 2012 end-page: 1031 article-title: An immune‐active tumor microenvironment favors clinical response to ipilimumab publication-title: Cancer Immunol. Immunother. – volume: 16 start-page: 3485 year: 2010 end-page: 3494 article-title: Tremelimumab in combination with exemestane in patients with advanced breast cancer and treatment‐associated modulation of inducible costimulator expression on patient T cells publication-title: Clin. Cancer Res. – volume: 53 start-page: 27 year: 1975 end-page: 42 article-title: A new analysis of allogeneic interactions publication-title: Aust. J. Exp. Biol. Med. Sci. – volume: 28 start-page: 1099 year: 2010 end-page: 1105 article-title: Overall survival analysis of a Phase II randomized controlled trial of a poxviral‐based PSA‐targeted immunotherapy in metastatic castration‐resistant prostate cancer publication-title: J. Clin. Oncol. – volume: 28 year: 2010 article-title: CTLA‐4 blockade with ipilimumab increases peripheral CD8+ T cells: correlation with clinical outcomes publication-title: J. Clin. Oncol. – volume: 9 start-page: 562 year: 2003 end-page: 567 article-title: Blockade of B7‐H1 improves myeloid dendritic cell‐mediated antitumor immunity publication-title: Nat. Med. – volume: 66 start-page: 10 year: 2005 end-page: 14 article-title: B7‐H1 glycoprotein blockade: a novel strategy to enhance immunotherapy in patients with renal cell carcinoma publication-title: Urology – volume: 15 start-page: 7412 year: 2009 end-page: 7420 article-title: Guidelines for the evaluation of immune therapy activity in solid tumors: immune‐related response criteria publication-title: Clin. Care Res. – volume: 19 start-page: 1223 year: 2007 end-page: 1234 article-title: Programmed death‐1 blockade enhances expansion and functional capacity of human melanoma antigen‐specific CTLs publication-title: Int. Immunol. – volume: 580 start-page: 755 year: 2006 end-page: 762 article-title: Interferon regulatory factor‐1 is prerequisite to the constitutive expression and IFN‐ ‐induced upregulation of B7‐H1 (CD274) publication-title: FEBS Lett. – volume: 366 start-page: 2455 year: 2012 end-page: 2465 article-title: Safety and activity of anti‐PD‐L1 antibody in patients with advanced cancer publication-title: N. Engl. J. Med. – volume: 32 start-page: 884 year: 2009 end-page: 885 article-title: No correlation between clinical response to CTLA‐4 blockade and presence of NY‐ESO‐1 antibody in patients with metastatic melanoma publication-title: J. Immunother. – volume: 59 start-page: 6028 year: 1999 end-page: 6032 article-title: Flt3‐ligand administration after radiation therapy prolongs survival in a murine model of metastatic lung cancer publication-title: Cancer Res. – volume: 364 start-page: 2517 year: 2011 end-page: 2526 article-title: Ipilimumab plus dacarbazine for previously untreated metastatic melanoma publication-title: N. Engl. J. Med. – volume: 5 start-page: 1365 year: 1999 end-page: 1369 article-title: B7‐H1, a third member of the B7 family, co‐stimulates T‐cell proliferation and interleukin‐10 secretion publication-title: Nat. Med. – volume: 23 start-page: 286 year: 2011 end-page: 292 article-title: Molecular profiling to identify relevant immune resistance mechanisms in the tumor microenvironment publication-title: Curr. Opin. Immunol. – volume: 27 issue: Suppl. year: 2009 article-title: Phase I trial of targeted therapy with PSA‐TRICOM vaccine (V) and ipilimumab (ipi) in patients (pts) with metastatic castration‐resistant prostate cancer (mCRPC) publication-title: J. Clin. Oncol. – volume: 190 start-page: 355 year: 1999 end-page: 366 article-title: Combination immunotherapy of B16 melanoma using anti‐cytotoxic T lymphocyte‐associated antigen 4 (CTLA‐4) and granulocyte/macrophage colony‐stimulating factor (GM‐CSF)‐producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation publication-title: J. Exp. Med. – volume: 180 start-page: 774 year: 2008 end-page: 782 article-title: ICOS controls the pool size of effector‐memory and regulatory T cells publication-title: J. Immunol. – volume: 18 start-page: 2039 year: 2012 end-page: 2047 article-title: CTLA‐4 blockade with ipilimumab: long‐term follow‐up of 177 patients with metastatic melanoma publication-title: Clin. Cancer Res. – volume: 169 start-page: 5538 year: 2002 end-page: 5545 article-title: Expression of programmed death 1 ligands by murine T cells and APC publication-title: J. Immunol. – volume: 170 start-page: 1257 year: 2003 end-page: 1266 article-title: Blockade of programmed death‐1 ligands on dendritic cells enhances T cell activation and cytokine production publication-title: J. Immunol. – volume: 96 start-page: 11476 year: 1999 end-page: 11481 article-title: In vivo blockade of CTLA‐4 enhances the priming of responsive T cells but fails to prevent the induction of tumor antigen‐specific tolerance publication-title: Proc. Natl. Acad. Sci. USA – volume: 23 start-page: viii15 issue: Suppl. 8 year: 2012 end-page: viii21 article-title: How recent advances in immunotherapy are changing the standard of care for patients with metastatic melanoma publication-title: Ann. Oncol. – volume: 10 start-page: 5094 year: 2004 end-page: 5100 article-title: B7‐H1 expression on non‐small cell lung cancer cells and its relationship with tumor‐infiltrating lymphocytes and their PD‐1 expression publication-title: Clin. Cancer Res. – volume: 11 start-page: 728 year: 2005 end-page: 734 article-title: Immune‐mediated inhibition of metastases after treatment with local radiation and CTLA‐4 blockade in a mouse model of breast cancer publication-title: Clin. Cancer Res. – volume: 198 start-page: 851 year: 2003 end-page: 862 article-title: Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma publication-title: J. Exp. Med. – volume: 56 start-page: 1173 year: 2007 end-page: 1182 article-title: Overexpression of B7‐H1 (PD‐L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers publication-title: Cancer Immunol. Immunother. – volume: 117 start-page: 3383 year: 2007 end-page: 3392 article-title: LAG‐3 regulates CD8+ T cell accumulation and effector function in murine self‐ and tumor‐tolerance systems publication-title: J. Clin. Invest. – volume: 63 start-page: 6501 year: 2003 end-page: 6505 article-title: B7‐H1 blockade augments adoptive T‐cell immunotherapy for squamous cell carcinoma publication-title: Cancer Res. – volume: 18 start-page: 6580 year: 2012 end-page: 6587 article-title: Molecular pathways: next‐generation immunotherapy—inhibiting programmed death‐ligand 1 and programmed death‐1 publication-title: Clin. Cancer Res. – volume: 116 start-page: 1767 year: 2010 end-page: 1775 article-title: Single‐institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival publication-title: Cancer – volume: 9 start-page: 204 year: 2011 article-title: A prospective Phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma publication-title: J. Transl. Med. – volume: 21 year: 2002 article-title: MDX‐010 (human anti‐CTLA4): a Phase I trial in malignant melanoma publication-title: Proc. Am. Soc. Clin. Oncol. – volume: 24 start-page: 2283 year: 2006 end-page: 2289 article-title: Enterocolitis in patients with cancer after antibody blockade of cytotoxic T‐lymphocyte‐associated antigen 4 publication-title: J. Clin. Oncol. – volume: 1 start-page: 407 year: 2012 end-page: 408 article-title: Abscopal but desirable: the contribution of immune responses to the efficacy of radiotherapy publication-title: Oncoimmunology – volume: 108 start-page: 16723 year: 2011 end-page: 16728 article-title: Integrated NY‐ESO‐1 antibody and CD8+ T‐cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab publication-title: Proc. Natl. Acad. Sci. USA – volume: 107 start-page: 7875 year: 2010 end-page: 7880 article-title: Tumor‐infiltrating NY‐ESO‐1‐specific CD8+ T cells are negatively regulated by LAG‐3 and PD‐1 in human ovarian cancer publication-title: Proc. Natl. Acad. Sci. USA – volume: 16 start-page: 2861 year: 2010 end-page: 2871 article-title: Preoperative CTLA‐4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial publication-title: Clin. Cancer Res. – volume: 105 start-page: 20410 year: 2008 end-page: 20415 article-title: CTLA‐4 blockade enhances polyfunctional NY‐ESO‐1 specific T cell responses in metastatic melanoma patients with clinical benefit publication-title: Proc. Natl. Acad. Sci. USA – volume: 69 start-page: 609 year: 2009 end-page: 615 article-title: Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM‐CSF publication-title: Cancer Res. – volume: 22 start-page: 329 year: 2004 end-page: 360 article-title: The three Es of cancer immunoediting publication-title: Annu. Rev. Immunol. – volume: 11 start-page: 5708 year: 2005 end-page: 5717 article-title: Expression of functional B7‐H2 and B7.2 costimulatory molecules and their prognostic implications in de novo acute myeloid leukemia publication-title: Clin. Cancer Res. – volume: 27 start-page: 15s issue: Suppl. year: 2009 article-title: Initial Phase II experience of ipilimumab (IPI) alone and in combination with radiotherapy (XRT) in patients with metastatic castration‐resistant prostate cancer (mCRPC) publication-title: J. Clin. Oncol. – volume: 110 start-page: 296 year: 2007 end-page: 304 article-title: Plasma cells from multiple myeloma patients express B7‐H1 (PD‐L1) and increase expression after stimulation with IFN‐{ } and TLR ligands via a MyD88‐, TRAF6‐, and MEK‐dependent pathway publication-title: Blood – volume: 30 start-page: 71 year: 2011 end-page: 82 article-title: How to improve the immunogenicity of chemotherapy and radiotherapy publication-title: Cancer Metastasis Rev. – volume: 366 start-page: 2035 year: 2012 article-title: Abscopal effect in a patient with melanoma publication-title: N. Engl. J. Med. – volume: 58 start-page: 823 year: 2009 end-page: 830 article-title: Ipilimumab: controversies in its development, utility and autoimmune adverse events publication-title: Cancer Immunol. Immunother. – volume: 363 start-page: 411 year: 2010 end-page: 422 article-title: Sipuleucel‐T immunotherapy for castration‐resistant prostate cancer publication-title: N. Engl. J. Med. – volume: 157 start-page: 9 year: 2009 end-page: 19 article-title: Cancer immunotherapy: co‐stimulatory agonists and co‐inhibitory antagonists publication-title: Clin. Exp. Immunol. – volume: 167 start-page: 1 year: 2012 end-page: 5 article-title: Ipilimumab: a novel immunomodulating therapy causing autoimmune hypophysitis: a case report and review publication-title: Eur. J. Endocrinol. – volume: 107 start-page: 4275 year: 2010 end-page: 4280 article-title: PD‐1 and CTLA‐4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors publication-title: Proc. Natl. Acad. Sci. USA – volume: 165 start-page: 302 year: 1987 end-page: 319 article-title: Antigen presentation by chemically modified splenocytes induces antigen‐specific T cell unresponsiveness in vitro and in vivo publication-title: J. Exp. Med. – volume: 57 start-page: 4036 year: 1997 end-page: 4041 article-title: Enhanced induction of antitumor T‐cell responses by cytotoxic T lymphocyte‐associated molecule‐4 blockade: the effect is manifested only at the restricted tumor‐bearing stages publication-title: Cancer Res. – volume: 8 start-page: 793 year: 2002 end-page: 800 article-title: Tumor‐associated B7‐H1 promotes T‐cell apoptosis: a potential mechanism of immune evasion publication-title: Nat. Med. – volume: 16 start-page: 1042 year: 2010 end-page: 1048 article-title: Phase II trial of tremelimumab (CP‐675,206) in patients with advanced refractory or relapsed melanoma publication-title: Clin. Care Res. – volume: 39 start-page: 1050 year: 2008 end-page: 1058 article-title: Programmed death 1 is a marker of angioimmunoblastic T‐cell lymphoma and B‐cell small lymphocytic lymphoma/chronic lymphocytic leukemia publication-title: Hum. Pathol. – volume: 106 start-page: 2729 year: 2009 end-page: 2734 article-title: Anti‐CTLA‐4 therapy results in higher CD4+ICOShi T cell frequency and IFN‐ levels in both nonmalignant and malignant prostate tissues publication-title: Proc. Natl. Acad. Sci. USA – volume: 19 start-page: 333 year: 2009 end-page: 334 article-title: Anti‐CTLA‐4 therapy‐related autoimmune hypophysitis in a melanoma patient publication-title: Melanoma Res. – volume: 101 start-page: 17174 year: 2004 end-page: 17179 article-title: Costimulatory B7‐H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target publication-title: Proc. Natl. Acad. Sci. USA – volume: 63 start-page: 7462 year: 2003 end-page: 7467 article-title: Expression of the B7‐related molecule B7‐H1 by glioma cells: a potential mechanism of immune paralysis publication-title: Cancer Res. – volume: 182 start-page: 5240 year: 2009 end-page: 5249 article-title: PD‐1 is a regulator of NY‐ESO‐1‐specific CD8+ T cell expansion in melanoma patients publication-title: J. Immunol. – volume: 28 issue: Suppl. year: 2010 article-title: Phase II trial of ipilimumab (IPI) and paclitaxel/carboplatin (P/C) in first‐line Stage IIIb/IV non‐small cell lung cancer (NSCLC) publication-title: J. Clin. Oncol. – volume: 26 issue: Suppl.; abs. LBA9011 year: 2008 article-title: Phase III, open‐label, randomized, comparative study of tremelimumab (CP‐675,206) and chemotherapy (temozolomide or dacarbazine) in patients with advanced melanoma publication-title: J. Clin. Oncol. – volume: 13 start-page: 29 year: 2010 end-page: 38 article-title: Anti‐CTLA‐4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes publication-title: Pituitary – volume: 30 issue: Suppl.: abs. 2512 year: 2012 article-title: Phase I study of MK‐3475 (anti‐PD‐1 monoclonal antibody) in patients with advanced solid tumors publication-title: J. Clin. Oncol. – volume: 65 start-page: 1089 year: 2005 end-page: 1096 article-title: Blockade of B7‐H1 and PD‐1 by monoclonal antibodies potentiates cancer therapeutic immunity publication-title: Cancer Res. – volume: 363 start-page: 711 year: 2010 end-page: 723 article-title: Improved survival with ipilimumab in patients with metastatic melanoma publication-title: N. Engl. J. Med. – volume: 33 start-page: 225 year: 2010 end-page: 235 article-title: Enhanced tumor eradication by combining CTLA‐4 or PD‐1 blockade with CpG therapy publication-title: J. Immunother. – volume: 94 start-page: 8099 year: 1997 end-page: 8103 article-title: Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer publication-title: Proc. Natl. Acad. Sci. USA – volume: 18 start-page: 1821 year: 2012 end-page: 1823 article-title: The antitumor immunity of ipilimumab: (T‐cell) memories to last a lifetime? publication-title: Clin. Cancer Res. – volume: 224 start-page: 141 year: 2008 end-page: 165 article-title: Cell intrinsic mechanisms of T‐cell inhibition and application to cancer therapy publication-title: Immunol. Rev. – volume: 108 start-page: 19 year: 2006 end-page: 24 article-title: Immunohistochemical localization of programmed death‐1 ligand‐1 (PD‐L1) in gastric carcinoma and its clinical significance publication-title: Acta Histochem. – volume: 104 start-page: 3360 year: 2007 end-page: 3365 article-title: Programmed cell death 1 ligand 1 and tumor‐infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer publication-title: Proc. Natl. Acad. Sci. USA – volume: 99 start-page: 12293 year: 2002 end-page: 12297 article-title: Involvement of PD‐L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD‐L1 blockade publication-title: Proc. Natl. Acad. Sci. USA – volume: 64 start-page: 4965 year: 2004 end-page: 4972 article-title: Immunotherapeutic potential of B7‐DC (PD‐L2) cross‐linking antibody in conferring antitumor immunity publication-title: Cancer Res. – volume: 11 start-page: 3887 year: 1992 end-page: 3895 article-title: Induced expression of PD‐1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death publication-title: EMBO J. – volume: 37 start-page: 499 year: 2010 end-page: 507 article-title: The emerging toxicity profiles of anti‐CTLA‐4 antibodies across clinical indications publication-title: Semin. Oncol. – volume: 104 start-page: 2084 year: 2005 end-page: 2091 article-title: Costimulatory molecule B7‐H1 in primary and metastatic clear cell renal cell carcinoma publication-title: Cancer – year: 2012 – volume: 11 start-page: 155 year: 2010 end-page: 164 article-title: Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double‐blind, multicentre, Phase II, dose‐ranging study publication-title: Lancet Oncol. – volume: 33 start-page: 828 year: 2010 end-page: 833 article-title: Phase 2 trial of single agent ipilimumab (anti‐CTLA‐4) for locally advanced or metastatic pancreatic adenocarcinoma publication-title: J. Immunother. – volume: 13 start-page: 1810 year: 2007 end-page: 1815 article-title: A pilot trial of CTLA‐4 blockade with human anti‐CTLA‐4 in patients with hormone‐refractory prostate cancer publication-title: Clin. Cancer Res. – volume: 24 start-page: 3089 year: 2006 end-page: 3094 article-title: Placebo‐controlled Phase III trial of immunologic therapy with sipuleucel‐T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer publication-title: J. Clin. Oncol. – volume: 17 start-page: 133 year: 2005 end-page: 144 article-title: PD‐1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells publication-title: Int. Immunol. – volume: 271 start-page: 1734 year: 1996 end-page: 1736 article-title: Enhancement of antitumor immunity by CTLA‐4 blockade publication-title: Science – volume: 366 start-page: 925 year: 2012 end-page: 931 article-title: Immunologic correlates of the abscopal effect in a patient with melanoma publication-title: N. Engl. J. Med. – volume: 15 start-page: 5379 year: 2009 end-page: 5388 article-title: Fractionated but not singledose radiotherapy induces an immune‐mediated abscopal effect when combined with anti‐CTLA‐4 antibody publication-title: Clin. Cancer Res. – volume: 66 start-page: 3381 year: 2006 end-page: 3385 article-title: Tumor B7‐H1 is associated with poor prognosis in renal cell carcinoma patients with long‐term follow‐up publication-title: Cancer Res. – volume: 4 start-page: 127ra37 year: 2012 article-title: Colocalization of inflammatory response with B7‐h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape publication-title: Sci. Transl. Med. – volume: 32 start-page: 4607 year: 2012 end-page: 4608 article-title: Ipilimumab‐induced immune‐related renal failure—a case report publication-title: Anticancer Res. – volume: 155 start-page: 172 year: 2004 end-page: 182 article-title: Interferon‐ enhances monocyte and dendritic cell expression of B7‐H1 (PD‐L1), a strong inhibitor of autologous T‐cell activation: relevance for the immune modulatory effect in multiple sclerosis publication-title: J. Neuroimmunol. – volume: 366 start-page: 2443 year: 2012 end-page: 2454 article-title: Safety, activity, and immune correlates of anti‐PD‐1 antibody in cancer publication-title: N. Engl. J. Med. – volume: 22 start-page: 113 year: 2010 end-page: 124 article-title: Chemotherapy and radiotherapy: cryptic anticancer vaccines publication-title: Semin. Immunol. – volume: 580 start-page: 755 year: 2006 ident: 2023013012333151700_B53 article-title: Interferon regulatory factor-1 is prerequisite to the constitutive expression and IFN-γ-induced upregulation of B7-H1 (CD274) publication-title: FEBS Lett. doi: 10.1016/j.febslet.2005.12.093 – volume: 157 start-page: 9 year: 2009 ident: 2023013012333151700_B6 article-title: Cancer immunotherapy: co-stimulatory agonists and co-inhibitory antagonists publication-title: Clin. Exp. Immunol. doi: 10.1111/j.1365-2249.2009.03912.x – volume: 65 start-page: 1089 year: 2005 ident: 2023013012333151700_B14 article-title: Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity publication-title: Cancer Res. doi: 10.1158/0008-5472.1089.65.3 – volume: 59 start-page: 6028 year: 1999 ident: 2023013012333151700_B114 article-title: Flt3-ligand administration after radiation therapy prolongs survival in a murine model of metastatic lung cancer publication-title: Cancer Res. – volume: 94 start-page: 25 ident: 2023013012333151700_B20 article-title: At the bench: Preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy publication-title: J. Leukoc. Biol. doi: 10.1189/jlb.1212621 – volume: 10 start-page: 5094 year: 2004 ident: 2023013012333151700_B66 article-title: B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-04-0428 – volume: 30 start-page: e76 year: 2012 ident: 2023013012333151700_B35 article-title: Posterior reversible encephalopathy syndrome during ipilimumab therapy for malignant melanoma publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2011.38.7886 – volume: 61 start-page: 1019 year: 2012 ident: 2023013012333151700_B96 article-title: An immune-active tumor microenvironment favors clinical response to ipilimumab publication-title: Cancer Immunol. Immunother. doi: 10.1007/s00262-011-1172-6 – volume: 30 start-page: 71 year: 2011 ident: 2023013012333151700_B109 article-title: How to improve the immunogenicity of chemotherapy and radiotherapy publication-title: Cancer Metastasis Rev. doi: 10.1007/s10555-011-9283-2 – volume: 23 start-page: 286 year: 2011 ident: 2023013012333151700_B94 article-title: Molecular profiling to identify relevant immune resistance mechanisms in the tumor microenvironment publication-title: Curr. Opin. Immunol. doi: 10.1016/j.coi.2010.11.013 – volume: 180 start-page: 774 year: 2008 ident: 2023013012333151700_B89 article-title: ICOS controls the pool size of effector-memory and regulatory T cells publication-title: J. Immunol. doi: 10.4049/jimmunol.180.2.774 – volume: 66 start-page: 10 year: 2005 ident: 2023013012333151700_B71 article-title: B7-H1 glycoprotein blockade: a novel strategy to enhance immunotherapy in patients with renal cell carcinoma publication-title: Urology doi: 10.1016/j.urology.2005.06.010 – volume: 11 start-page: 3887 year: 1992 ident: 2023013012333151700_B21 article-title: Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death publication-title: EMBO J. doi: 10.1002/j.1460-2075.1992.tb05481.x – volume: 24 start-page: 2283 year: 2006 ident: 2023013012333151700_B37 article-title: Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4 publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2005.04.5716 – volume: 23 start-page: viii15 year: 2012 ident: 2023013012333151700_B38 article-title: How recent advances in immunotherapy are changing the standard of care for patients with metastatic melanoma publication-title: Ann. Oncol. doi: 10.1093/annonc/mds258 – volume: 2 start-page: 439 year: 2002 ident: 2023013012333151700_B1 article-title: Activation rules: the two-signal theories of immune activation publication-title: Nat. Rev. Immunol. doi: 10.1038/nri823 – volume: 108 start-page: 16723 year: 2011 ident: 2023013012333151700_B87 article-title: Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab publication-title: Proc. Natl. Acad. Sci. USA doi: 10.1073/pnas.1110814108 – volume: 19 start-page: 333 year: 2009 ident: 2023013012333151700_B41 article-title: Anti-CTLA-4 therapy-related autoimmune hypophysitis in a melanoma patient publication-title: Melanoma Res. doi: 10.1097/CMR.0b013e32832e0bff – volume: 107 start-page: 7875 year: 2010 ident: 2023013012333151700_B74 article-title: Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer publication-title: Proc. Natl. Acad. Sci. USA doi: 10.1073/pnas.1003345107 – volume: 104 start-page: 2084 year: 2005 ident: 2023013012333151700_B55 article-title: Costimulatory molecule B7-H1 in primary and metastatic clear cell renal cell carcinoma publication-title: Cancer doi: 10.1002/cncr.21470 – volume: 106 start-page: 2729 year: 2009 ident: 2023013012333151700_B91 article-title: Anti-CTLA-4 therapy results in higher CD4+ICOShi T cell frequency and IFN-γ levels in both nonmalignant and malignant prostate tissues publication-title: Proc. Natl. Acad. Sci. USA doi: 10.1073/pnas.0813175106 – volume: 57 start-page: 4036 year: 1997 ident: 2023013012333151700_B9 article-title: Enhanced induction of antitumor T-cell responses by cytotoxic T lymphocyte-associated molecule-4 blockade: the effect is manifested only at the restricted tumor-bearing stages publication-title: Cancer Res. – volume: 7 start-page: 682 year: 1995 ident: 2023013012333151700_B12 article-title: Manipulation of costimulatory signals to enhance antitumor T-cell responses publication-title: Curr. Opin. Immunol. doi: 10.1016/0952-7915(95)80077-8 – volume: 363 start-page: 711 year: 2010 ident: 2023013012333151700_B24 article-title: Improved survival with ipilimumab in patients with metastatic melanoma publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1003466 – volume: 53 start-page: 27 year: 1975 ident: 2023013012333151700_B3 article-title: A new analysis of allogeneic interactions publication-title: Aust. J. Exp. Biol. Med. Sci. doi: 10.1038/icb.1975.3 – volume: 18 start-page: 1821 year: 2012 ident: 2023013012333151700_B49 article-title: The antitumor immunity of ipilimumab: (T-cell) memories to last a lifetime? publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-12-0409 – volume: 9 start-page: 133 year: 2002 ident: 2023013012333151700_B51 article-title: Expression and regulation of the PD-L1 immunoinhibitory molecule on microvascular endothelial cells publication-title: Microcirculation doi: 10.1080/713774061 – volume: 366 start-page: 925 year: 2012 ident: 2023013012333151700_B115 article-title: Immunologic correlates of the abscopal effect in a patient with melanoma publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1112824 – volume: 116 start-page: 1767 year: 2010 ident: 2023013012333151700_B84 article-title: Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival publication-title: Cancer doi: 10.1002/cncr.24951 – volume: 24 start-page: 3089 year: 2006 ident: 2023013012333151700_B46 article-title: Placebo-controlled Phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2005.04.5252 – volume: 32 start-page: 4607 year: 2012 ident: 2023013012333151700_B34 article-title: Ipilimumab-induced immune-related renal failure—a case report publication-title: Anticancer Res. – volume: 9 start-page: 204 year: 2011 ident: 2023013012333151700_B95 article-title: A prospective Phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma publication-title: J. Transl. Med. doi: 10.1186/1479-5876-9-204 – volume: 99 start-page: 12293 year: 2002 ident: 2023013012333151700_B17 article-title: Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade publication-title: Proc. Natl. Acad. Sci. USA doi: 10.1073/pnas.192461099 – volume: 170 start-page: 1257 year: 2003 ident: 2023013012333151700_B64 article-title: Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production publication-title: J. Immunol. doi: 10.4049/jimmunol.170.3.1257 – volume: 21 year: 2002 ident: 2023013012333151700_B22 article-title: MDX-010 (human anti-CTLA4): a Phase I trial in malignant melanoma publication-title: Proc. Am. Soc. Clin. Oncol. – volume: 108 start-page: 19 year: 2006 ident: 2023013012333151700_B61 article-title: Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance publication-title: Acta Histochem. doi: 10.1016/j.acthis.2006.01.003 – volume: 30 year: 2012 ident: 2023013012333151700_B80 article-title: Phase I study of MK-3475 (anti-PD-1 monoclonal antibody) in patients with advanced solid tumors publication-title: J. Clin. Oncol. doi: 10.1200/jco.2012.30.15_suppl.2512 – volume: 101 start-page: 17174 year: 2004 ident: 2023013012333151700_B56 article-title: Costimulatory B7-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target publication-title: Proc. Natl. Acad. Sci. USA doi: 10.1073/pnas.0406351101 – volume: 155 start-page: 172 year: 2004 ident: 2023013012333151700_B52 article-title: Interferon-β enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosis publication-title: J. Neuroimmunol. doi: 10.1016/j.jneuroim.2004.06.013 – volume: 15 start-page: 7412 year: 2009 ident: 2023013012333151700_B29 article-title: Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria publication-title: Clin. Care Res. doi: 10.1158/1078-0432.CCR-09-1624 – volume: 109 start-page: 1499 year: 2007 ident: 2023013012333151700_B57 article-title: PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression publication-title: Cancer doi: 10.1002/cncr.22588 – volume: 182 start-page: 5240 year: 2009 ident: 2023013012333151700_B73 article-title: PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patients publication-title: J. Immunol. doi: 10.4049/jimmunol.0803245 – volume: 117 start-page: 3383 year: 2007 ident: 2023013012333151700_B13 article-title: LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems publication-title: J. Clin. Invest. doi: 10.1172/JCI31184 – volume: 190 start-page: 355 year: 1999 ident: 2023013012333151700_B43 article-title: Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation publication-title: J. Exp. Med. doi: 10.1084/jem.190.3.355 – volume: 105 start-page: 14987 year: 2008 ident: 2023013012333151700_B90 article-title: CTLA-4 blockade increases IFNγ-producing CD4 + ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients publication-title: Proc. Natl. Acad. Sci. USA doi: 10.1073/pnas.0806075105 – volume: 58 start-page: 823 year: 2009 ident: 2023013012333151700_B32 article-title: Ipilimumab: controversies in its development, utility and autoimmune adverse events publication-title: Cancer Immunol. Immunother. doi: 10.1007/s00262-008-0653-8 – volume: 16 start-page: 1042 year: 2010 ident: 2023013012333151700_B26 article-title: Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma publication-title: Clin. Care Res. doi: 10.1158/1078-0432.CCR-09-2033 – volume: 114 start-page: 1537 year: 2009 ident: 2023013012333151700_B75 article-title: Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired publication-title: Blood doi: 10.1182/blood-2008-12-195792 – volume: 366 start-page: 2455 year: 2012 ident: 2023013012333151700_B31 article-title: Safety and activity of anti-PD-L1 antibody in patients with advanced cancer publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1200694 – volume: 167 start-page: 1 year: 2012 ident: 2023013012333151700_B39 article-title: Ipilimumab: a novel immunomodulating therapy causing autoimmune hypophysitis: a case report and review publication-title: Eur. J. Endocrinol. doi: 10.1530/EJE-12-0167 – volume: 363 start-page: 411 year: 2010 ident: 2023013012333151700_B45 article-title: Sipuleucel-T immunotherapy for castration-resistant prostate cancer publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1001294 – volume: 14 start-page: 3044 year: 2008 ident: 2023013012333151700_B78 article-title: Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-07-4079 – volume: 107 start-page: 4275 year: 2010 ident: 2023013012333151700_B106 article-title: PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors publication-title: Proc. Natl. Acad. Sci. USA doi: 10.1073/pnas.0915174107 – volume: 9 start-page: 562 year: 2003 ident: 2023013012333151700_B15 article-title: Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity publication-title: Nat. Med. doi: 10.1038/nm863 – volume: 30 start-page: 802 year: 2006 ident: 2023013012333151700_B68 article-title: Programmed death-1 (PD-1) is a marker of germinal center-associated T cells and angioimmunoblastic T-cell lymphoma publication-title: Am. J. Surg. Pathol. doi: 10.1097/01.pas.0000209855.28282.ce – volume: 96 start-page: 11476 year: 1999 ident: 2023013012333151700_B11 article-title: In vivo blockade of CTLA-4 enhances the priming of responsive T cells but fails to prevent the induction of tumor antigen-specific tolerance publication-title: Proc. Natl. Acad. Sci. USA doi: 10.1073/pnas.96.20.11476 – volume: 1 start-page: 407 year: 2012 ident: 2023013012333151700_B111 article-title: Abscopal but desirable: the contribution of immune responses to the efficacy of radiotherapy publication-title: Oncoimmunology doi: 10.4161/onci.20074 – volume: 16 start-page: 2861 year: 2010 ident: 2023013012333151700_B93 article-title: Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-10-0569 – volume: 39 start-page: 1050 year: 2008 ident: 2023013012333151700_B67 article-title: Programmed death 1 is a marker of angioimmunoblastic T-cell lymphoma and B-cell small lymphocytic lymphoma/chronic lymphocytic leukemia publication-title: Hum. Pathol. doi: 10.1016/j.humpath.2007.11.012 – volume: 31 start-page: 51 year: 2013 ident: 2023013012333151700_B108 article-title: Immunogenic cell death in cancer therapy publication-title: Annu. Rev. Immunol. doi: 10.1146/annurev-immunol-032712-100008 – volume: 18 start-page: 6580 year: 2012 ident: 2023013012333151700_B82 article-title: Molecular pathways: next-generation immunotherapy—inhibiting programmed death-ligand 1 and programmed death-1 publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-12-1362 – volume: 13 start-page: 1810 year: 2007 ident: 2023013012333151700_B102 article-title: A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-06-2318 – volume: 15 start-page: 5379 year: 2009 ident: 2023013012333151700_B112 article-title: Fractionated but not singledose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-09-0265 – volume: 56 start-page: 1173 year: 2007 ident: 2023013012333151700_B58 article-title: Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers publication-title: Cancer Immunol. Immunother. doi: 10.1007/s00262-006-0266-z – volume: 18 start-page: 2039 year: 2012 ident: 2023013012333151700_B48 article-title: CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-11-1823 – volume: 19 start-page: 1223 year: 2007 ident: 2023013012333151700_B72 article-title: Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLs publication-title: Int. Immunol. doi: 10.1093/intimm/dxm091 – volume: 69 start-page: 609 year: 2009 ident: 2023013012333151700_B99 article-title: Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-08-3529 – volume: 4 start-page: 299 year: 2012 ident: 2023013012333151700_B36 article-title: Characteristics and management of immunerelated adverse effects associated with ipilimumab, a new immunotherapy for metastatic melanoma publication-title: Cancer Manag. Res. doi: 10.2147/CMAR.S31873 – volume: 94 start-page: 8099 year: 1997 ident: 2023013012333151700_B8 article-title: Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer publication-title: Proc. Natl. Acad. Sci. USA doi: 10.1073/pnas.94.15.8099 – volume: 28 start-page: 1099 year: 2010 ident: 2023013012333151700_B47 article-title: Overall survival analysis of a Phase II randomized controlled trial of a poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2009.25.0597 – volume: 104 start-page: 3360 year: 2007 ident: 2023013012333151700_B59 article-title: Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer publication-title: Proc. Natl. Acad. Sci. USA doi: 10.1073/pnas.0611533104 – volume: 27 start-page: 15s year: 2009 ident: 2023013012333151700_B100 article-title: Initial Phase II experience of ipilimumab (IPI) alone and in combination with radiotherapy (XRT) in patients with metastatic castration-resistant prostate cancer (mCRPC) publication-title: J. Clin. Oncol. doi: 10.1200/jco.2009.27.15_suppl.5138 – volume: 28 year: 2010 ident: 2023013012333151700_B103 article-title: Phase II trial of ipilimumab (IPI) and paclitaxel/carboplatin (P/C) in first-line Stage IIIb/IV non-small cell lung cancer (NSCLC) publication-title: J. Clin. Oncol. doi: 10.1200/jco.2010.28.15_suppl.7531 – volume: 28 year: 2010 ident: 2023013012333151700_B85 article-title: CTLA-4 blockade with ipilimumab increases peripheral CD8+ T cells: correlation with clinical outcomes publication-title: J. Clin. Oncol. doi: 10.1200/jco.2010.28.15_suppl.2555 – volume: 11 start-page: 483 year: 1999 ident: 2023013012333151700_B10 article-title: CTLA-4 blockade reverses CD8+ T cell tolerance to tumor by a CD4+ T cell- and IL-2-dependent mechanism publication-title: Immunity doi: 10.1016/S1074-7613(00)80123-5 – volume: 13 start-page: 2151 year: 2007 ident: 2023013012333151700_B60 article-title: Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-06-2746 – volume: 224 start-page: 141 year: 2008 ident: 2023013012333151700_B42 article-title: Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy publication-title: Immunol. Rev. doi: 10.1111/j.1600-065X.2008.00649.x – volume: 11 start-page: 728 year: 2005 ident: 2023013012333151700_B113 article-title: Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.728.11.2 – volume: 26 year: 2008 ident: 2023013012333151700_B27 article-title: Phase III, open-label, randomized, comparative study of tremelimumab (CP-675,206) and chemotherapy (temozolomide or dacarbazine) in patients with advanced melanoma publication-title: J. Clin. Oncol. doi: 10.1200/jco.2008.26.15_suppl.lba9011 – volume: 73 start-page: 57 year: 1997 ident: 2023013012333151700_B44 article-title: Specific blockade of CTLA-4/B7 interactions results in exacerbated clinical and histologic disease in an actively-induced model of experimental allergic encephalomyelitis publication-title: J. Neuroimmunol. doi: 10.1016/S0165-5728(96)00168-3 – volume: 22 start-page: 113 year: 2010 ident: 2023013012333151700_B110 article-title: Chemotherapy and radiotherapy: cryptic anticancer vaccines publication-title: Semin. Immunol. doi: 10.1016/j.smim.2010.03.001 – volume: 30 start-page: 825 year: 2007 ident: 2023013012333151700_B104 article-title: Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis publication-title: J. Immunother. doi: 10.1097/CJI.0b013e318156e47e – volume-title: Clinical activity and safety of anti-programmed death-1 (PD-1) (BMS-936558/MDX-1106/ONO-4538) in patients (PTS) with advanced melanoma (MEL) in ESMO year: 2012 ident: 2023013012333151700_B79 doi: 10.1093/annonc/mds404 – volume: 5 start-page: 1365 year: 1999 ident: 2023013012333151700_B76 article-title: B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion publication-title: Nat. Med. doi: 10.1038/70932 – volume: 22 start-page: 329 year: 2004 ident: 2023013012333151700_B5 article-title: The three Es of cancer immunoediting publication-title: Annu. Rev. Immunol. doi: 10.1146/annurev.immunol.22.012703.104803 – volume: 192 start-page: 1027 year: 2000 ident: 2023013012333151700_B77 article-title: Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation publication-title: J. Exp. Med. doi: 10.1084/jem.192.7.1027 – volume: 105 start-page: 20410 year: 2008 ident: 2023013012333151700_B86 article-title: CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit publication-title: Proc. Natl. Acad. Sci. USA doi: 10.1073/pnas.0810114105 – volume: 13 start-page: 5 year: 2013 ident: 2023013012333151700_B98 article-title: CTLA-4 blockade in tumor models: an overview of preclinical and translational research publication-title: Cancer Immun. – volume: 8 start-page: 793 year: 2002 ident: 2023013012333151700_B62 article-title: Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion publication-title: Nat. Med. doi: 10.1038/nm730 – volume: 33 start-page: 225 year: 2010 ident: 2023013012333151700_B107 article-title: Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapy publication-title: J. Immunother. doi: 10.1097/CJI.0b013e3181c01fcb – volume: 27 year: 2009 ident: 2023013012333151700_B83 article-title: Association of peripheral blood absolute lymphocyte count (ALC) and clinical activity in patients (pts) with advanced melanoma treated with ipilimumab publication-title: J. Clin. Oncol. doi: 10.1200/jco.2009.27.15_suppl.3020 – volume: 27 year: 2009 ident: 2023013012333151700_B101 article-title: Phase I trial of targeted therapy with PSA-TRICOM vaccine (V) and ipilimumab (ipi) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) publication-title: J. Clin. Oncol. doi: 10.1200/jco.2009.27.15_suppl.5144 – volume-title: Efficacy and Safety of MK-3475 in Patients with Advanced Melanoma in Society for Melanoma Research year: 2012 ident: 2023013012333151700_B81 – volume: 64 start-page: 4965 year: 2004 ident: 2023013012333151700_B19 article-title: Immunotherapeutic potential of B7-DC (PD-L2) cross-linking antibody in conferring antitumor immunity publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-03-3025 – volume: 110 start-page: 296 year: 2007 ident: 2023013012333151700_B54 article-title: Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{γ} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway publication-title: Blood doi: 10.1182/blood-2006-10-051482 – volume: 271 start-page: 1734 year: 1996 ident: 2023013012333151700_B7 article-title: Enhancement of antitumor immunity by CTLA-4 blockade publication-title: Science doi: 10.1126/science.271.5256.1734 – volume: 11 start-page: 155 year: 2010 ident: 2023013012333151700_B23 article-title: Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, Phase II, dose-ranging study publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(09)70334-1 – volume: 16 start-page: 3485 year: 2010 ident: 2023013012333151700_B92 article-title: Tremelimumab in combination with exemestane in patients with advanced breast cancer and treatment-associated modulation of inducible costimulator expression on patient T cells publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-10-0505 – volume: 4 start-page: 127ra37 year: 2012 ident: 2023013012333151700_B97 article-title: Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape publication-title: Sci. Transl. Med. doi: 10.1126/scitranslmed.3003689 – volume: 198 start-page: 851 year: 2003 ident: 2023013012333151700_B69 article-title: Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma publication-title: J. Exp. Med. doi: 10.1084/jem.20031074 – volume: 11 start-page: 5708 year: 2005 ident: 2023013012333151700_B70 article-title: Expression of functional B7-H2 and B7.2 costimulatory molecules and their prognostic implications in de novo acute myeloid leukemia publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-04-2672 – volume: 63 start-page: 6501 year: 2003 ident: 2023013012333151700_B16 article-title: B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma publication-title: Cancer Res. – volume: 366 start-page: 2443 year: 2012 ident: 2023013012333151700_B30 article-title: Safety, activity, and immune correlates of anti-PD-1 antibody in cancer publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1200690 – volume: 32 start-page: 884 year: 2009 ident: 2023013012333151700_B88 article-title: No correlation between clinical response to CTLA-4 blockade and presence of NY-ESO-1 antibody in patients with metastatic melanoma publication-title: J. Immunother. doi: 10.1097/CJI.0b013e3181affbf0 – volume: 17 start-page: 133 year: 2005 ident: 2023013012333151700_B18 article-title: PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells publication-title: Int. Immunol. doi: 10.1093/intimm/dxh194 – volume: 165 start-page: 302 year: 1987 ident: 2023013012333151700_B2 article-title: Antigen presentation by chemically modified splenocytes induces antigen-specific T cell unresponsiveness in vitro and in vivo publication-title: J. Exp. Med. doi: 10.1084/jem.165.2.302 – volume: 37 start-page: 499 year: 2010 ident: 2023013012333151700_B33 article-title: The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications publication-title: Semin. Oncol. doi: 10.1053/j.seminoncol.2010.09.007 – volume: 63 start-page: 7462 year: 2003 ident: 2023013012333151700_B63 article-title: Expression of the B7-related molecule B7-H1 by glioma cells: a potential mechanism of immune paralysis publication-title: Cancer Res. – volume: 28 year: 2010 ident: 2023013012333151700_B28 article-title: Evaluation of baseline serum C-reactive protein (CRP) and benefit from tremelimumab compared to chemotherapy in first-line melanoma publication-title: J. Clin. Oncol. doi: 10.1200/jco.2010.28.15_suppl.2609 – volume: 33 start-page: 828 year: 2010 ident: 2023013012333151700_B105 article-title: Phase 2 trial of single agent ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma publication-title: J. Immunother. doi: 10.1097/CJI.0b013e3181eec14c – volume: 364 start-page: 2517 year: 2011 ident: 2023013012333151700_B25 article-title: Ipilimumab plus dacarbazine for previously untreated metastatic melanoma publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1104621 – volume: 66 start-page: 3381 year: 2006 ident: 2023013012333151700_B65 article-title: Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-05-4303 – volume: 169 start-page: 5538 year: 2002 ident: 2023013012333151700_B50 article-title: Expression of programmed death 1 ligands by murine T cells and APC publication-title: J. Immunol. doi: 10.4049/jimmunol.169.10.5538 – volume: 366 start-page: 2035 year: 2012 ident: 2023013012333151700_B116 article-title: Abscopal effect in a patient with melanoma publication-title: N. Engl. J. Med. doi: 10.1056/NEJMc1203984 – volume: 169 start-page: 1042 year: 1970 ident: 2023013012333151700_B4 article-title: A theory of self-nonself discrimination publication-title: Science doi: 10.1126/science.169.3950.1042 – volume: 13 start-page: 29 year: 2010 ident: 2023013012333151700_B40 article-title: Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes publication-title: Pituitary doi: 10.1007/s11102-009-0193-z – reference: 22203769 - J Clin Oncol. 2012 Feb 20;30(6):e76-8 – reference: 21074065 - Semin Oncol. 2010 Oct;37(5):499-507 – reference: 21933959 - Proc Natl Acad Sci U S A. 2011 Oct 4;108(40):16723-8 – reference: 9307290 - Cancer Res. 1997 Sep 15;57(18):4036-41 – reference: 23049279 - Cancer Manag Res. 2012;4:299-307 – reference: 22123319 - J Transl Med. 2011;9:204 – reference: 9058759 - J Neuroimmunol. 1997 Mar;73(1-2):57-62 – reference: 23157435 - Annu Rev Immunol. 2013;31:51-72 – reference: 18759925 - Immunol Rev. 2008 Aug;224:141-65 – reference: 18178815 - J Immunol. 2008 Jan 15;180(2):774-82 – reference: 22146893 - Cancer Immunol Immunother. 2012 Jul;61(7):1019-31 – reference: 22271879 - Clin Cancer Res. 2012 Apr 1;18(7):2039-47 – reference: 22754758 - Oncoimmunology. 2012 Jul 1;1(4):407-408 – reference: 15701862 - Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):728-34 – reference: 10430624 - J Exp Med. 1999 Aug 2;190(3):355-66 – reference: 20160101 - Proc Natl Acad Sci U S A. 2010 Mar 2;107(9):4275-80 – reference: 19202079 - Proc Natl Acad Sci U S A. 2009 Feb 24;106(8):2729-34 – reference: 1396582 - EMBO J. 1992 Nov;11(11):3887-95 – reference: 10626784 - Cancer Res. 1999 Dec 15;59(24):6028-32 – reference: 25977344 - Clin Cancer Res. 2015 Oct 1;21(19):4286-93 – reference: 22658127 - N Engl J Med. 2012 Jun 28;366(26):2443-54 – reference: 17898045 - Int Immunol. 2007 Oct;19(10):1223-34 – reference: 11932780 - Microcirculation. 2002 Apr;9(2):133-45 – reference: 16115907 - Clin Cancer Res. 2005 Aug 15;11(16):5708-17 – reference: 8573312 - Curr Opin Immunol. 1995 Oct;7(5):682-6 – reference: 20004617 - Lancet Oncol. 2010 Feb;11(2):155-64 – reference: 12538684 - J Immunol. 2003 Feb 1;170(3):1257-66 – reference: 12091876 - Nat Med. 2002 Aug;8(8):793-800 – reference: 238498 - Aust J Exp Biol Med Sci. 1975 Feb;53(1):27-42 – reference: 15611321 - Int Immunol. 2005 Feb;17(2):133-44 – reference: 17340590 - Cancer. 2007 Apr 15;109(8):1499-505 – reference: 22621637 - N Engl J Med. 2012 May 24;366(21):2035; author reply 2035-6 – reference: 3029267 - J Exp Med. 1987 Feb 1;165(2):302-19 – reference: 9223321 - Proc Natl Acad Sci U S A. 1997 Jul 22;94(15):8099-103 – reference: 14612546 - Cancer Res. 2003 Nov 1;63(21):7462-7 – reference: 23625198 - J Leukoc Biol. 2013 Jul;94(1):25-39 – reference: 20385810 - Proc Natl Acad Sci U S A. 2010 Apr 27;107(17):7875-80 – reference: 16208700 - Cancer. 2005 Nov 15;104(10):2084-91 – reference: 16530813 - Acta Histochem. 2006;108(1):19-24 – reference: 16819321 - Am J Surg Pathol. 2006 Jul;30(7):802-10 – reference: 15256470 - Cancer Res. 2004 Jul 15;64(14):4965-72 – reference: 17186290 - Cancer Immunol Immunother. 2007 Aug;56(8):1173-82 – reference: 12704383 - Nat Med. 2003 May;9(5):562-7 – reference: 12421930 - J Immunol. 2002 Nov 15;169(10):5538-45 – reference: 16413538 - FEBS Lett. 2006 Feb 6;580(3):755-62 – reference: 23060594 - Anticancer Res. 2012 Oct;32(10):4607-8 – reference: 4194660 - Science. 1970 Sep 11;169(3950):1042-9 – reference: 17363736 - Blood. 2007 Jul 1;110(1):296-304 – reference: 18483370 - Clin Cancer Res. 2008 May 15;14(10):3044-51 – reference: 20143434 - Cancer. 2010 Apr 1;116(7):1767-75 – reference: 22918923 - Ann Oncol. 2012 Sep;23 Suppl 8:viii15-21 – reference: 20460488 - Clin Cancer Res. 2010 May 15;16(10):2861-71 – reference: 20445343 - J Immunother. 2010 Apr;33(3):225-35 – reference: 21639810 - N Engl J Med. 2011 Jun 30;364(26):2517-26 – reference: 20479064 - Clin Cancer Res. 2010 Jul 1;16(13):3485-94 – reference: 19706802 - Clin Cancer Res. 2009 Sep 1;15(17):5379-88 – reference: 15342209 - J Neuroimmunol. 2004 Oct;155(1-2):172-82 – reference: 17363537 - Clin Cancer Res. 2007 Mar 15;13(6):1810-5 – reference: 19074257 - Proc Natl Acad Sci U S A. 2008 Dec 23;105(51):20410-5 – reference: 20818862 - N Engl J Med. 2010 Jul 29;363(5):411-22 – reference: 22397654 - N Engl J Med. 2012 Mar 8;366(10):925-31 – reference: 23087408 - Clin Cancer Res. 2012 Dec 15;18(24):6580-7 – reference: 21298323 - Cancer Metastasis Rev. 2011 Mar;30(1):71-82 – reference: 15297412 - Clin Cancer Res. 2004 Aug 1;10(15):5094-100 – reference: 19934295 - Clin Cancer Res. 2009 Dec 1;15(23):7412-20 – reference: 22338019 - Clin Cancer Res. 2012 Apr 1;18(7):1821-3 – reference: 11015443 - J Exp Med. 2000 Oct 2;192(7):1027-34 – reference: 16809734 - J Clin Oncol. 2006 Jul 1;24(19):3089-94 – reference: 20100959 - J Clin Oncol. 2010 Mar 1;28(7):1099-105 – reference: 19752745 - J Immunother. 2009 Oct;32(8):884-5 – reference: 20525992 - N Engl J Med. 2010 Aug 19;363(8):711-23 – reference: 17932562 - J Clin Invest. 2007 Nov;117(11):3383-92 – reference: 16585157 - Cancer Res. 2006 Apr 1;66(7):3381-5 – reference: 22495490 - Eur J Endocrinol. 2012 Jul;167(1):1-5 – reference: 17360651 - Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3360-5 – reference: 19147575 - Cancer Res. 2009 Jan 15;69(2):609-15 – reference: 22461641 - Sci Transl Med. 2012 Mar 28;4(127):127ra37 – reference: 22658128 - N Engl J Med. 2012 Jun 28;366(26):2455-65 – reference: 19380770 - J Immunol. 2009 May 1;182(9):5240-9 – reference: 19659765 - Clin Exp Immunol. 2009 Jul;157(1):9-19 – reference: 10581077 - Nat Med. 1999 Dec;5(12):1365-9 – reference: 18479731 - Hum Pathol. 2008 Jul;39(7):1050-8 – reference: 15705911 - Cancer Res. 2005 Feb 1;65(3):1089-96 – reference: 15032581 - Annu Rev Immunol. 2004;22:329-60 – reference: 20842054 - J Immunother. 2010 Oct;33(8):828-33 – reference: 16710025 - J Clin Oncol. 2006 May 20;24(15):2283-9 – reference: 12218188 - Proc Natl Acad Sci U S A. 2002 Sep 17;99(19):12293-7 – reference: 21185705 - Curr Opin Immunol. 2011 Apr;23(2):286-92 – reference: 14559843 - Cancer Res. 2003 Oct 1;63(19):6501-5 – reference: 19423728 - Blood. 2009 Aug 20;114(8):1537-44 – reference: 19512947 - Melanoma Res. 2009 Oct;19(5):333-4 – reference: 23390376 - Cancer Immun. 2013;13:5 – reference: 20403709 - Semin Immunol. 2010 Jun;22(3):113-24 – reference: 20086001 - Clin Cancer Res. 2010 Feb 1;16(3):1042-8 – reference: 8596936 - Science. 1996 Mar 22;271(5256):1734-6 – reference: 18049334 - J Immunother. 2007 Nov-Dec;30(8):825-30 – reference: 12093010 - Nat Rev Immunol. 2002 Jun;2(6):439-46 – reference: 15569934 - Proc Natl Acad Sci U S A. 2004 Dec 7;101(49):17174-9 – reference: 10500201 - Proc Natl Acad Sci U S A. 1999 Sep 28;96(20):11476-81 – reference: 17404099 - Clin Cancer Res. 2007 Apr 1;13(7):2151-7 – reference: 18818309 - Proc Natl Acad Sci U S A. 2008 Sep 30;105(39):14987-92 – reference: 19639414 - Pituitary. 2010;13(1):29-38 – reference: 12975453 - J Exp Med. 2003 Sep 15;198(6):851-62 – reference: 16194701 - Urology. 2005 Nov;66(5 Suppl):10-4 – reference: 10549630 - Immunity. 1999 Oct;11(4):483-93 – reference: 19198837 - Cancer Immunol Immunother. 2009 May;58(5):823-30 |
| SSID | ssj0003260 |
| Score | 2.5566914 |
| SecondaryResourceType | review_article |
| Snippet | Clinical Review for Basic Researchers: Treating patients with CTLA‐4 and PD‐1 pathway blocking antibodies, plus clinical progress and application of agents in... It is increasingly appreciated that cancers are recognized by the immune system, and under some circumstances, the immune system may control or even eliminate... Clinical Review for Basic Researchers: Treating patients with CTLA-4 and PD-1 pathway blocking antibodies, plus clinical progress and application of agents in... |
| SourceID | pubmedcentral proquest pubmed crossref wiley highwire |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 41 |
| SubjectTerms | Antibodies, Blocking - therapeutic use Clinical Trials as Topic CTLA-4 Antigen - antagonists & inhibitors CTLA-4 Antigen - immunology endpoints Humans Immunotherapy Neoplasms - immunology Neoplasms - therapy overall survival Paired Basic-Translational Reviews Programmed Cell Death 1 Receptor - antagonists & inhibitors Programmed Cell Death 1 Receptor - immunology tumor |
| Title | At the Bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy |
| URI | http://www.jleukbio.org/content/94/1/41.abstract https://onlinelibrary.wiley.com/doi/abs/10.1189%2Fjlb.1212631 https://www.ncbi.nlm.nih.gov/pubmed/23667165 https://www.proquest.com/docview/1381100978 https://www.proquest.com/docview/1551624382 https://pubmed.ncbi.nlm.nih.gov/PMC4051187 |
| Volume | 94 |
| WOSCitedRecordID | wos000328840800006&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVWIB databaseName: Wiley Online Library Full Collection 2020 customDbUrl: eissn: 1938-3673 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0003260 issn: 0741-5400 databaseCode: DRFUL dateStart: 19970101 isFulltext: true titleUrlDefault: https://onlinelibrary.wiley.com providerName: Wiley-Blackwell |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1ta9swED62dIN92Uu7F29r0aAMNjC1FPlF-5a2C2OEUkYK-SYkWWYeqTOSdCHf9hP2G_dLdmc7pmGlMGYQGPtsLOlk3Ul3zwNwKHJX8Iz2B71QoSyMD23ibOjjvrdZTghWDdlEenaWTSbqvI3NoVyYBh-iW3CjkVH_r2mAG9uykGSEkfltagkaQSSURb0jUHNlD3ZOvwwvRt2vGG2TqMHh5BQBELUJeviCo2uPb09JG5jgm0zOvyMnr1u09ZQ0fPSflXkMD1tblA0a5XkCd3y1C3uDCv3wyzV7y-ro0HrZfRfuN6SV6z0YD5YMrUZ27HOi-vzATsajwe-fvyQWZqqcnZ_iGcdicaKklXi8uiztjOIVWVkxR4o2ZyVlprT5X-uncDH8OD75FLbcDKFDn4aHVoqCqNOV8NJzG5tIFjjVGRnnNrfSptwL4cj_cjkeInYyKgrjlLUoapL-M-hVs8q_AFYIopmRnOc-lyihpDJSpZHj3qi-5wG833SPdi1wOfFnTHXtwGRKY-vptvUCOOyEvzd4HTeL7W_6WS8uzXSK3Sr0arVSUnMt8f6bTedrHG-0iWIqP7taaI4mDq-zX26Rod1HQVusATxvFKb7GNFPEvRR4wDSLVXqBAjve_tOVX6tcb_RtiZy-ADe1ap0W_3059ExQam9_AfZV_BA1FwfFIv8GnrL-ZXfh3vux7JczA_gbjrJDtoB9geMLiri |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1ti9NAEB6kp-gXX-58iXq6wiEohMtuN23Wb707y6mxHNKD-7bsbjYY6aXS9iz95k_wN_pLnEnScMXjQCwslGYakuxMdmZ25nkA9kTmcp7Q_qAXKpS58aHtORv6uOttkhGCVU020R-NkrMzddIk3KgXpsaHaBNuZBnV-5oMnBLStZUnBJL5bWIJG0H0qI16S6IixR3YOvoyPE3bdzE6J1ENxMmpBCBqOvTwBPuX_r65Jq1xgq_yOf8unbzs0lZr0vDe_97NfbjbeKNsUKvPA7jhy23YGZQYiZ-v2GtW1YdWifdtuFXTVq52YDxYMPQb2YHPiOzzHTscp4PfP39JHMyUGTs5wm8ch8WlknLx-OuisFOqWGRFyRyp2owV1JvSdICtHsLp8P348Dhs2BlCh1END60UOZGnK-Gl5zY2kcxxsTMyzmxmpe1zL4SjCMxl-BGxk1GeG6esRVHT6z6CTjkt_RNguSCiGcl55jOJEkoqI1U_ctwb1fU8gLfr-dGugS4nBo2JrkKYRGl8erp5egHstcLfa8SOq8V21xOt5-dmMsF5FXq5XCqpuZZ4_NV69jVaHG2jmNJPL-aao5PDq_6Xa2Ro_1HQJmsAj2uNaS9GdHs9jFLjAPobutQKEOL35pGy-Fohf6N3TfTwAbypdOm6-9Mf0wMCU3v6D7Iv4fbx-HOq0w-jT8_gjqiYP6gy-Tl0FrMLvws33Y9FMZ-9aOzsD0xDLeo |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1ti9NAEF7kTsUvvtz5EvV0hUNQCGa3mzTrt97V4kspRXpw35Z9C0Z66dH2LP3mT_A3-kuc2aThiseBGFgIySQk2ZnszO7M8xByyJ0tWI7rg57LWBTaxyazJvZpx5vcIYJVTTbRHY3y01M5bibcsBamxodoJ9zQMsL_Gg3cn7uitvIcQTK_Tw1iI_AMy6h3RSozMMzd_tfBybD9F4NzktRAnAxTAJKmQg9u8O7S5dtj0gYn-Cqf8-_UycsubRiTBvf-923uk7uNN0p7tfo8IDd8tUf2exVE4mdr-pqG_NAw8b5HbtW0let9MuktKfiN9Mg7JPt8T48nw97vn78ENKorR8d92GPQDAyVOBcPR5elmWHGIi0ralHV5rTE2pSmAmz9kJwMPkyOP8YNO0NsIaphsRG8QPJ0yb3wzKQ6EQUMdlqkzjgjTJd5zi1GYNbBxlMrkqLQVhoDojrrPCI71azyTwgtOBLNCMacdwIkpJBayG5imdey41lE3m76R9kGuhwZNKYqhDC5VPD1VPP1InLYCp_XiB1Xix1sOlotzvR0Cv3K1Wq1kkIxJeD8q03vK7A4XEbRlZ9dLBQDJ4eF-pdrZHD9keMia0Qe1xrTPgzvZBlEqWlEulu61Aog4vf2mar8FpC_wbtGeviIvAm6dN37qc_DIwRTe_oPsi_J7XF_oIafRl-ekTs8EH9gYvJzsrOcX_gDctP-WJaL-YvGzP4Al0wtZQ |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=At+the+Bedside%3A+CTLA-4-+and+PD-1-blocking+antibodies+in+cancer+immunotherapy&rft.jtitle=Journal+of+leukocyte+biology&rft.au=Margaret+K.+Callahan&rft.au=Jedd+D.+Wolchok&rft.date=2013-07-01&rft.pub=Society+for+Leukocyte+Biology&rft.issn=0741-5400&rft.eissn=1938-3673&rft.volume=94&rft.issue=1&rft.spage=41&rft_id=info:doi/10.1189%2Fjlb.1212631&rft_id=info%3Apmid%2F23667165&rft.externalDBID=n%2Fa&rft.externalDocID=www94_1_41 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0741-5400&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0741-5400&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0741-5400&client=summon |